



Cite this: RSC Adv., 2021, 11, 35806

Journey of anthraquinones as anticancer agents – a systematic review of recent literature

M. Shaheer Malik,^a Reem I. Alsantali,^b Rabab S. Jassas,^c Abdulrahman A. Alsimaree,^d Riyaz Syed,^e Meshari A. Alsharif,^a Kulkarni Kalpana,^f Moataz Morad,^a Ismail I. Althagafi^a and Saleh A. Ahmed^g

Anthraquinones are privileged chemical scaffolds that have been used for centuries in various therapeutic applications. The anthraquinone moiety forms the core of various anticancer agents. However, the emergence of drug-resistant cancers warrants the development of new anticancer agents. The research endeavours towards new anthraquinone-based compounds are increasing rapidly in recent years. They are used as a core chemical template to achieve structural modifications, resulting in the development of new anthraquinone-based compounds as promising anticancer agents. Mechanistically, most of the anthraquinone-based compounds inhibit cancer progression by targeting essential cellular proteins. Herein, we review new anthraquinone analogues that have been developed in recent years as anticancer agents. This includes a systematic review of the recent literature (2005–2021) on anthraquinone-based compounds in cell-based models and key target proteins such as kinases, topoisomerases, telomerases, matrix metalloproteinases and G-quadruplexes involved in the viability of cancer cells. In addition to this, the developments in PEG-based delivery of anthraquinones and the toxicity aspects of anthraquinone derivatives are also discussed. The review dispenses a compact background knowledge to understanding anthraquinones for future research on the expansion of anticancer therapeutics.

Received 27th July 2021
Accepted 6th October 2021

DOI: 10.1039/d1ra05686g

rsc.li/rsc-advances

^aDepartment of Chemistry, Faculty of Applied Sciences, Umm Al-Qura University, Makkah 21955, Saudi Arabia. E-mail: msalik@uqu.edu.sa; saahmed@uqu.edu.sa

^bDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P. O. Box 11099, Taif 21944, Saudi Arabia

^cDepartment of Chemistry, Jamoum University College, Umm Al-Qura University, 21955 Makkah, Saudi Arabia

^dDepartment of Basic Science (Chemistry), College of Science and Humanities, Shaqra University, Afif, Saudi Arabia

^eCentalla Discovery, JHUB, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad 500085, India

^fDepartment of Humanities and Sciences (Chemistry), Gokaraju Rangaraju Institute of Engineering and Technology, Bachupally, Hyderabad 500090, India

^gDepartment of Chemistry, Faculty of Science, Assiut University, 71516 Assiut, Egypt



M. Shaheer Malik is currently Assistant Professor in chemistry at Umm Al-Qura University, Makkah (Saudi Arabia). He carried out his doctoral studies in organic chemistry at the Indian Institute of Chemical Technology, Hyderabad, and was awarded a PhD from Osmania University, India. Subsequently, he moved for a postdoctoral assignment to Yonsei University, Seoul (Korea),

working in biocatalysis. His research interest deals with the design and synthesis of novel chemical compounds as pharmaceutical agents and the application of enzymes in organic transformations. He regularly contributes and reviews research findings towards the advancement of science in his area of interest.



Prof. Dr Saleh A. Ahmed was born in Assiut, Egypt in 1968 where he undertook undergraduate and post-graduate studies. He received his Bachelor and MSc from Assiut University, Egypt and PhD in photochemistry (photochromism) under the supervision of Prof. Heinz Dürr at Saarland University, Saarbrücken, Germany. He worked as postdoctoral fellow, senior researcher and visiting professor in France (CNRS fellow), Japan (JSPS

fellow), Germany (AvH, DFG and DAAD fellows), Italy (TEMPUS fellow) and USA (Arab fund fellow). His current research interests include synthesis and photophysical properties of novel organic compounds, electronic devices and solar energy conversion, photocatalysis, nanomaterials and their applications, fluorophores and biologically active molecules.



1. Introduction

Anthraquinone (1), a quinone-containing chemical compound, is enriched with a myriad of interesting biological profiles that can be harnessed for multiple therapeutic applications with stepwise iterations. Quinones, a cyclic diketone structural compound, form the basis for the subgroup 9,10-anthraquinones (a.k.a 9,10-dioxoanthracenes, anthracene-9,10-diones, anthradiones, dioxoanthracenes, 9,10-anthrachinons and anthracene-9,10-quinones).¹ The carbonyl function is present on the 9th and 10th carbon positions of the quinone moiety. The rigidity, planarity, and aromaticity of the anthraquinone system have been studied widely with respect to its pharmacological properties. In particular, the planarity of this molecule provides the advantage of embedding in the DNA double helix, thus acting as a DNA intercalator. An interesting historical journey of anthraquinones in anticancer drug development is depicted in Fig. 1. The anthraquinone moiety can be found in nature, for example in emodin (2), aloe-emodin (3), rhein (4), and chrysophanol (5) or utilized as a starting material in the development of many anticancer agents (Fig. 2).²

A brief historical account of anthraquinones as a chemical class is provided here. The earliest recorded discovery of anthraquinone was in 1840 when Laurent oxidized anthracene to synthesize anthraquinone. He named the chemical “anthracenuse”, while it was termed “oxanthracen” by Anderson independently.³ Interestingly, the presently used name “anthraquinone” was proposed by Graebe and Libermann in the year 1868, almost three decades later to earlier nomenclature.⁴ Similar to Laurent, Fritsche reported the synthesis of anthraquinone *via* oxidation of anthracene with chromic acid.⁵ In a stimulating development, Graebe and Liebermann proposed the structural formula of anthracene and successfully established the relationship between anthraquinone and alizarin (6) by synthesizing alizarin from anthracene.^{4,6} Finally, in 1873, Fittig proposed the correct diketone structure of

anthraquinone, which is widely used today,⁷ and more than 75 natural anthraquinones were identified from various sources like lichens, marine sources, fungi, and medicinal plants of various families.^{8,9}

Anthraquinones have drawn the interest of chemists to access diversely substituted derivatives *via* different synthetic protocols. In recent years, most of the anthraquinone derivatives synthesized as potential anticancer agents utilize commercially available anthraquinones as starting material. However, several synthetic approaches are available to synthesize substituted anthraquinones, and a few of them are summarised here (Table 1). A classical approach to access anthraquinone ring is the intramolecular cyclization of 2-(4-alkylbenzoyl)benzoic acid derivatives in pyrophosphoryl chloride to afford 7-substituted anthraquinone analogs (entry 1). Another classical strategy of Diels–Alder cycloaddition was improved by treating naphthaquinone with cyclohexadiene to give anthraquinone moiety in the presence of ionic liquid (entry 2). In another approach to synthesize 2-substituted 1,3-dihydroxy anthraquinones, phthalic anhydride was treated with 2-methyl resorcinol to afford damnacanthal and nordamnacanthal (entry 3). Similarly, the 7-substituted anthraquinones were reported to be obtained from reacting appropriate *N,N*-diethyl benzamide with *ortho*-bromo benzaldehyde (entry 4). In an iridium catalysed route, the 1,4-dibutyl anthraquinones were synthesized from 1,1'-(1,2-phenylene)bis(hept-2-yn-1-one) and ethyne derivatives in the presence of organophosphorus compounds under refluxing toluene (entry 5). In addition to this, anthracene and anthracene-based compounds were converted to anthraquinones by utilizing different catalytic strategies.^{10–13}

Because of their plethora of biological properties, anthraquinones have become an important class of compounds in drug discovery. In traditional medicines, anthraquinone compounds have been used for many centuries, and aloe is one of the classic examples.¹⁹ Many anthraquinone derivatives have




Fig. 1 Milestones in anthraquinone journey as an anticancer agent.




Fig. 2 Naturally occurring anthraquinone molecules from different sources.

also been identified in bacteria, fungi, and insects.²⁰ In addition to their biological properties, many natural and synthetic anthraquinones are well known for their uses in the textile industry, paints, imaging photocleavable protecting groups, devices and biochips, foods, cosmetics, and pharmaceuticals.^{21–26} Moreover, they are useful catalysts in several chemical and biogeochemical processes like the degradation of

contaminants exploiting the redox potential.^{27,28} More prominently, the scaffold is widely recognized for its diverse pharmacological profiles. A quick glance at the interesting activities of anthraquinone reveals its applications in antifungal,²⁹ antiviral,^{30–32} antimalarial,³³ antimicrobial,^{34,35} antiplatelet,³⁶ antidiabetic,^{37,38} neuroprotective,³⁹ laxative,⁴⁰ and many more therapeutic settings. To discuss a few, antibacterial anthraquinone, emodin from the

Table 1 Synthetic protocols leading to anthraquinone derivatives

S. no.	Synthetic approach	Reference
1	<p>R = H, Cl, OCH₃</p>	14
2		15
3		16
4		17
5	<p>2 mol% [Ir(cod)Cl]₂ 4 mol% DPPE Toluene, reflux, 20 h</p>	18



roots of *Rheum ribes*, displayed a MIC value of $39 \mu\text{g mL}^{-1}$ against *Staphylococcus aureus*.⁴¹ Antithrombotic compound PSB0702, exhibited potent activity in binding studies with K_i value of 21 nM,⁴² and the dehydration of gallic acid yielded a potent anti-malarial agent rufigallol, active against *Plasmodium falciparum* with an IC_{50} value of 35 nM.⁴³ The planarity and rigidity of anthraquinones, discussed at the start of this review, has attracted many medicinal chemists to explore their anticancer potential. The 1,4-anthraquinone (7) exhibits anticancer activity by inhibiting crucial proteins and nucleic acid synthesis in cellular machinery.⁴⁴ There are a plethora of molecules that have been derived from core anthraquinones scaffold aimed at various cancer targets. This immense interest stems from the marketed anticancer drugs such as mitoxantrone, doxorubicin and epirubicin with anthraquinone ring structure. The new-age drug delivery techniques have further enhanced the target and site-specific delivery of these derivatives. In addition, the research towards the design and development of new anthraquinone derivatives is rising day by day owing to their profound biological activity.

In specific, anthraquinone-based compounds plays a significant role in the treatment of cancer by chemotherapeutics agents. Some of the anthraquinone scaffold containing drugs such as daunorubicin (8), idarubicin (9), doxorubicin (10), epirubicin (11), valrubicin (12), pixantrone (13), mitoxantrone (14) are currently in clinical use for various types of cancer treatments (Fig. 3).⁴⁵

In the past, several research groups reported the anticancer potential of anthraquinones and their derivatives against different cancer cell lines as well as cancer targets. Cancer, a complex disease, is characterized by the uncontrolled growth of abnormal cells that can be invasive or metastatic and is the second leading cause of human deaths worldwide.⁴⁶ The majority of the anticancer drugs have failed at the clinical level due to non-selectivity, toxicity, low therapeutic window, and drug resistance.⁴⁷ Hence, the design and development of novel

anticancer drugs with fewer side effects are the primary focus of cancer drug discovery. Anthraquinones are potential anticancer agents which are easily metabolized and excreted renally after conversion to more hydrophilic glucuronides by uridine diphosphate glucuronosyl transferase (UGT) enzymes in the human body.⁴⁸ The amount and percentage of each glucuronide formed from each anthraquinone in the liver and intestinal microsomes differ and is not always equal to the total glucuronides formed from each anthraquinone.⁴⁹ The historical evidence of the therapeutic application of anthraquinones can be seen in the plant herb *Compendium of Materia Medica*, which is frequently used in Chinese traditional medicine.⁵⁰ Later, the laxative effect of rhubarb roots rich in aloe-emodin, emodin, rhein, chrysophanol, and subsequent glucopyranosides was reported. Not only the phyto-based anthraquinones, the synthetic derivatives of anthraquinones were also found to be promising therapeutic agents against a wide array of diseases. The antitumour activities of anthraquinones include inhibition of cancer cell proliferation, invasion, migration, metastasis, induction of cellular apoptosis and tumour angiogenesis, regulation of the host immune response, antioxidant, anti-inflammatory, reversing tumour cell multidrug resistance, and so on. Furthermore, different research groups described the anticancer potential of anthraquinones by the inhibition of various targets like protein kinases topoisomerases, telomerase, ecto-nucleotidases, matrix metalloproteinases (MMPs), DNA quadruplex and many more. The developments in the field of anthraquinone-based anticancer agents is reviewed based primarily based on the biological targets.^{2,20,51}

Herein, based on the abundance of literature from 2005 to date, we reviewed and recapitulated the developments in anthraquinones research in the context of anticancer agents to serve as a source and guiding tool for further investigation. The article provides insights into the systematic improvements to develop anthraquinone compounds towards anticancer therapeutics from 2005 onwards. This is followed by a critical discussion on the target protein-specific anthraquinone derivatives. The studies on the selective delivery of anthraquinones at specific sites exploiting the PEG-based approach and the toxicity profile of the anthraquinones are highlighted. Finally, a structure–activity relationship of the anthraquinone moiety on the antitumour potency is also discussed. This approach will allow readers to get a diverse and holistic perspective on the potential of anthraquinones and can guide them in designing novel anthraquinone-derived anticancer agents.

2. Development of non-specific cytotoxic anthraquinone derivatives

In recent decades, extensive research has been carried out to explore the anticancer potency of new anthraquinone derivatives. However, most of these reports deal with cell-based assays that assess the cytotoxicity of new anthraquinone derivatives against selected cancer cell lines. In these studies, the biochemical assays to determine the mechanism of action are not generally undertaken. For the purpose of better




Fig. 3 FDA approved drugs containing anthraquinone nucleus.

understanding, the research from 2005 to date are reviewed in a year wise manner.

2.1 2005–2008

In general, anthraquinones and their derivatives show a unique antiproliferative activity. However, several researchers have made significant modifications in the structure from their initial discovery, resulting in the development of new anthraquinone derivatives with promising anticancer activity against various cancer types. Teng *et al.* reported the cytotoxic potency of 1,3-dihydroxy-9,10-anthraquinone compounds against different human cancer cell lines like HepG2, Hep3B, HT-29, and MCF-7. Among all the compounds synthesized, the anthraquinone derivative (**15**) showed selective cytotoxicity towards HepG2 cells with an ED_{50} value of 1.23 μ M. Also, another derivative, **16**, exhibited good activity against MCF-7 cells (Fig. 4). Further, the mechanistic studies revealed that compound **16** induces cell cycle arrest in G2/M phase and causes cell death *via* apoptosis.⁵² In another investigation, Dzieduszycka *et al.* described the anticancer potential of tetracyclic anthraquinone fused pyridine conjugates. The cytotoxic potential of the synthesized derivatives was examined on human cell lines such as human promyelocytic leukaemia (HL-60) and vincristine resistant (HL-60/VINC) and doxorubicin-resistant (HL-60/DX) cell lines. The anthraquinone analogue **17** exhibited decent activity against sensitive as well as resistant cell lines. It showed cytotoxicity activity of 311 nM, 1012 nM, and 667 nM against HL-60 cells, HL-60/VINC, and HL-60/DX. In addition, other derivatives of the series **18** and **19** displayed good activity towards HL-60 with IC_{50} values of 146 nM and 327 nM, respectively. The same compounds showed good to moderate activity against drug-resistant cell lines as well.⁵³

Similarly, Siwy *et al.* synthesized a series of 1,3-(oxytetraethylenoxy)cyclotriphosphazene derivatives and examined their antileukemic activity against MOLT4, L 1210, HL-60, and P388 cell lines. The derivatives **20** and **21** unveiled promising antiproliferative activity against MOLT4 cells with ID_{50} values of 2.1 and 1.14 μ g mL^{-1} , respectively.⁵⁴ Valderrama *et al.* designed and examined the biological activity of anthraquinone epoxides and their isomerization products. The biological activity was investigated against human cancer gastric epithelial cells (AGS). Further, the non-toxic nature of the synthesized derivatives was studied on normal human lung cells (MRC-5). Among all the derivatives, **22** and **23** showed potential anticancer activity against AGS cells with IC_{50} values of 4.1 and 4.9 μ M, respectively (Fig. 4).⁵⁴ Likewise, Tietze *et al.* reported the synthesis of anthraquinone analogues that are derived from the natural products mensacarcin, islandicin, and chrysophanol. Later, the cytotoxicity of synthesized derivatives was studied against human lung carcinoma cell lines (A549). The compound mensacarcin and its analogue **24** displayed promising antitumour activity with ED_{50} values of 1.6 and 11.6 μ M, respectively (Fig. 5).⁵⁵

In another study, Huang *et al.* synthesized a series of 34 analogues of 2,7-bis-substituted amido-anthraquinone (**25**) and evaluated their effects on cancer cell proliferation and telomerase activity. Most of the derivatives showed promising anti-cancer and telomerase inhibitory activity.⁵⁶ Click chemistry approach was used by Wang *et al.* to design and synthesize water-soluble anthraquinone derivatives. The anticancer activity evaluation of the same was performed on BGC gastric cancer cells along with mechanistic studies such as generation of reactive oxygen species, loss of mitochondrial membrane potential, transition of mitochondrial permeability, cell cycle arrest, and the release of cytochrome C. The derivative **26** exhibited promising antiproliferative activity against BGC cells with an IC_{50} of 4.02 μ M. Further, the same derivative induced




Fig. 4 Structures of anthraquinone derivatives reported in the year 2005–2006.






Fig. 5 Structures of anthraquinone analogs reported in the year 2007–2012.

cancer cell death *via* apoptosis. At a concentration of 25 μM , the majority of the cells (39.4%) entered into the apoptotic phase.⁵⁷

2.2 2009–2012

Yang *et al.* synthesized and reported the anticancer activity of oxiranyl and thiiranyl phenolic compounds. They investigated the cytotoxic potential of synthesized derivatives against a panel of different human cancer cells such as MDA-MB-231, LNCaP, DU145, and PC3 cells. The derivatives 27 and 28 demonstrated good activity towards PC3 cells with IC_{50} values of 2.5 and 4.0 μM , respectively. In addition, derivative 27 showed significant topoisomerase activity at 10 μM .⁵⁸ In yet another study, Jin *et al.* reported the synthesis of 1,4-bis(dimethylamino)-9,10-anthraquinone derivatives and assessed their biological evaluation against mouse leukemic tumour cells (p388). Most of the synthesized derivatives exhibited good to moderate activity against p388 cells. The analogue 29 showed an ED_{50} value of 1.3 $\mu\text{g mL}^{-1}$ while analogue 30 exhibited 1.5 $\mu\text{g mL}^{-1}$ against the tested tumour cells.⁵⁹

Tu *et al.* synthesized different anthraquinones derivatives that include 3-(3-alkylaminopropoxy)-9,10-anthraquinone and 1-hydroxy-3-(3-alkylaminopropoxy)-9,10-anthraquinone and evaluated their cytotoxicity towards different human cancer cell lines such as human urothelial carcinoma cells (NTUB1) and human prostate cancer cells (PC3). The derivatives 31 and 32 showed good anticancer activity against PC3 cells with IC_{50} values of 7.64 and 8.89 μM , respectively. Further, various

mechanistic studies like increased ROS production, cell cycle arrest, immuno-fluorescent staining, and gene expression of p21, p53, Bax, and cyclin B1 were investigated. The studies revealed that compound 31 induces apoptotic cell death by arresting the cell growth in G2/M phase with up-regulation of p21, p53, Bax, and cyclin B1.⁶⁰

2.3 2012–2014

Feng *et al.* reported the antiproliferative activity of phytochemical-based anthraquinones such as 3-hydroxy-1,5,6-trimethoxy-2-methyl-9,10-anthraquinone, also referred to as PCON6 (33) (Fig. 5). The authors studied the anticancer potential of PCON6 against a panel of 15 different cancer cell lines that includes a group of 11 non-lung cancer cell lines and four NSCLC cell lines. The most active compound arrested the cell growth in almost all the tested cell lines. However, non-small cell lung cancer (H520) and breast cancer (MCF7) were more sensitive to PCON6 treatment. The compound exhibited IC_{50} values of 7.8 and 10.2 μM against H520 and MCF7 cells, respectively. Other mechanistic studies revealed that the compound arrested the cell growth in the S-phase of the cell cycle by inducing apoptosis-mediated cell death in tested cell lines.⁶¹

In another study, Marković *et al.* synthesized anthraquinone-thiosemicarbazone derivatives and tested their anticancer potency against different human cancer cells such as HeLa, A549, K562, MDA-MB-453, MDA-MB-361. Almost all the

compounds exhibited good cytotoxicity against the tested cell lines. Most of the derivatives showed good specific activity towards K562 cells. The derivatives **34** and **35** showed promising anticancer activity against K562 cells with IC_{50} values of 2.17 and 2.35 μ M, respectively (Fig. 6). Notably, derivative **36** displayed good activity against HeLa cells with an IC_{50} value of 7.66 μ M. Further, **36** induced cell cycle arrest in the sub-G1 phase and promoted apoptosis in HeLa cells.⁶²

Bhasin *et al.* reported the synthesis of a series of substituted anthraquinones as well as 1,4-naphthoquinones and examined their biological activity against human prostate cancer cells (DU-145) and colon cancer (HT-29). Among the synthesized, anthraquinone **37** showed good antiproliferative activity against DU145 and HT-29 cells with IC_{50} values of 10.2 μ M and 8.5 μ M, respectively, while its analogue **38** exhibited 11.5 μ M IC_{50} value towards DU-145 and 10.4 μ M IC_{50} value against HT-29 cells.⁶³ Castro *et al.* synthesized a series of 1-azabenzanthrone analogues, their 2,3-dihydro derivatives, and substituted 9,10-anthracenediones. Later, the authors examined their anticancer potential towards four different human cancer cells such as gastric adenocarcinoma (AGS), lung cancer cells (SK-MES-1), bladder cancer cells (J82), and myelocytic leukaemia cells (HL-60). Among the synthesized, compounds **39** and **40** exhibited promising antiproliferative activity against gastric adenocarcinoma cells with IC_{50} values of 1.5 and 3.3 μ M, respectively.⁶⁴

Similarly, Lee *et al.* examined the anticancer potential of seven anthraquinones derived small molecules which are previously synthesized in their laboratory and screened against the NCI's 60 panel of human cancer cells comprising colon cancer, NSCLC, ovarian cancer, breast cancer, leukaemia, renal cancer, prostate cancer, CNS, and melanoma cancer. Amongst

the series, seven derivatives showed promising anticancer activity against all the tested cell lines. However, compound **41** exhibited promising activity and inhibited PARP enzyme (65%) at 10 μ M in a dose-dependent manner.⁶⁵ In another investigation, Liang *et al.* reported the synthesis and biological examination of new anthraquinone analogues. Afterward, they examined the c-Met kinase inhibition activity in A549 cells. Derivatives such **42** and **43** elicited good c-Met kinase inhibitory activity with IC_{50} values of 1.2 and 4.0 μ M, respectively.⁶⁶

Taher *et al.* synthesized two series of bis-anthraquinone derivatives and evaluated their biological potential against different human cancer cell lines. Among the synthesized, five derivatives were selected for studying the anticancer potential towards a panel of 60 NCI human cancer cell lines. The derivative **44** showed potent activity against all the tested cell lines (Fig. 6). It also showed very good anticancer activity against colon cancer cells (HCT-116) with a GI_{50} value of 0.3 μ M.⁶⁷ Kolundžija *et al.* designed and synthesized a class of imine derivatives of hybrid chalcones containing anthraquinone derivatives and examined their *in vitro* cytotoxicity against HeLa, LS174, and A549 cancer cell lines. The derivatives **45** and **46** inhibited the proliferation of HeLa cells at concentrations of 1.45 μ M and 1.82 μ M, respectively (Fig. 7). Further, the compounds in this series elevated the levels of caspase-3 and -8 and showed strong anti-angiogenic activity.⁶⁸

Almutairi *et al.* reported the synthesis of hybrids of celecoxib and 2-amino anthraquinone derivatives and carried out cytotoxicity profile against hepatic carcinoma cells (HepG2). The hybrid molecules **47** and **48** displayed good activity against HepG2 cells with IC_{50} values of 3.74 and 3.92 μ g mL⁻¹, respectively.⁶⁹ In another investigation, Chen *et al.* studied the




Fig. 6 Structures of anthraquinone derivatives reported in the year 2013.






Fig. 7 Structures of anthraquinone derivatives reported in the year of 2014.

anticancer potential of NSC745885 (**49**) in oral squamous carcinoma cells. The mechanistic studies such as annexin V staining, caspase expression, and other xenograft mouse model studies revealed that compound **49** is a potential therapeutic drug for treating oral squamous cell carcinoma.⁷⁰

Sangthong *et al.* reported the synthesis of anthracene-9,10-dione derivatives, and their anticancer potential against human papillomavirus (HPV) positive cancer cell line, CaSki. The derivative **50** showed good activity against the tested cell line with an IC_{50} value of 0.3 μM . Further studies demonstrated that the derivative arrested the cell growth in G2/M phase of the cell cycle and up-regulated the expression of p53 while down-regulating Bcl-2 gene.⁷¹ Similarly, Zhang *et al.* synthesized a series of azasugar-modified 2-mono substituted, 2,6- and 2,7-

bis substituted anthraquinone analogs and examined the anticancer activity against human breast cancer cells (MCF-7). The azasugar-anthraquinone derivative **51** showed superior activity against MCF-7 cells with an IC_{50} of 17.3 μM .⁷²

2.4 2015–2016

From the literature, it was observed that most anticancer drugs either interact with DNA or inhibit DNA synthesis.⁷³ In this context, Zuravka *et al.* synthesized bis-3-chloropiperidine tethered anthraquinone (**52**) nucleus (Fig. 8).⁷⁴ The compound **52** was tested for its reactivity towards DNA using chlorambucil as a positive control. Results indicated that the compound binds at the guanine sites of supercoiled plasmid and duplex oligonucleotide and causes DNA cleavage. It was further concluded that




Fig. 8 Structures of anthraquinone derivatives reported in the year 2015–2017.

the anthraquinone nucleus of the compound was more effective in driving DNA intercalation than its naphthalene derivative.

Similarly, Prati *et al.* synthesized 2-phenoxy-1,4-naphthoquinones derivatives and tested their activity against HT-29 and IGROV-1 cancer cell lines along with HDF non-cancerous cell line. The most active compound **53** was found to inhibit the tested cell lines at an IC_{50} of 2.70 and 1.43 μM , respectively. Further, the compounds that showed promising anti-tumour activity were analysed for their reactive oxygen consumption in bovine heart mitochondria.⁷⁵ The main focus of a study reported by Lin *et al.* was to explore the binding mechanism of compound NSC749235 (**54**) to human telomeric G-quadruplex DNA, one of the vital targets in cancer progression. The enzymatic assay was evaluated by measuring the thermodynamic stability and affinity of telomeric G-quadruplex DNA *via* FRET melting assay. The results indicated that the ligands selectively stabilized the potassium form of human telomeric G-quadruplex DNA compared to the other forms. Further, the cytotoxic activity of the compounds was evaluated in HeLa and A549 cell lines using daunorubicin as a reference compound. The derivative **54** exhibited effective inhibitory activity against HeLa cell line. The stabilization of potassium-containing telomeric G-quadruplex DNA by **54** led to ΔT_m values ranging from 3.66 to 8.04 $^{\circ}C$. Compound **54** exhibits inhibitory activity against the HeLa and A549, with IC_{50} values ranging from 5.54 to 14.54 μM . The results indicated that HeLa cell line was much more sensitive to the compound **54** than the A549 cell line. All the studies collectively showed that NSC749235 (**54**) serves as a scaffold for designing new anticancer chemical entities.⁷⁶

2.5 2017–2019

Zheng *et al.* synthesized quaternary ammonium salts of anthraquinone and tested their antiproliferative activities against A375, BGC-823, HepG2, and 8-HELf cancer cells. Among the tested compounds, the derivative **55** induced apoptosis and significantly increased ROS levels in A375 cells (Fig. 8). The derivative **55** exhibited IC_{50} values of 1.39 μM , 2.79

μM and 4.12 μM concentrations on A375, BGC-823 and HepG2 cell lines, respectively. Furthermore, the apoptotic capability was validated by tracing the indicator proteins caspase-3 and P53 using the western blot technique.⁷⁷ Okumura *et al.* synthesized compounds intending to establish and understand the relation between redox properties and antitumour activity of anthraquinones with a hydroxyl and methoxy group (**56**) (Fig. 9). The synthesized derivatives with different substitutions like hydroxy and methoxy at the 4th, 5th, and 8th positions of anthraquinone were studied for their redox behaviour using cyclic voltammograms (CVs). The redox studies indicated that the oxidative behaviours are different for each derivative. To further understand the pattern behind it, the authors performed molecular orbital energy calculations. It was found that the LUMO energies of the compounds were identical, while the HOMO energies varied depending on the position of the substituent. Cytotoxic studies against HL-60 and HP100 cells (using LDH activity assay) indicated that oxidized radicals played a significant role in inducing cell death.⁷⁸ The toxicity towards HL-60 increased with the increase in the concentration of **56**. However, the toxicity in relation to HP100 was less than half the toxicity to HL-60, indicating that H_2O_2 is involved in the process leading to cell death. Specifically, the cytotoxicity observed against HL-60 could be ascribed to reactive oxygen species (ROS) originating from electron transfer to oxygen accompanying the formation of reduced or oxidized compound **56** radicals.⁷⁸ In another investigation, Roa-Linares *et al.* synthesized 27 terphenyl-1,4-naphthoquinone (NQ), 1,4-anthraquinone (AQ), and heterocycle-fused quinone (HetQ) derivatives to evaluate their cytotoxicity against HeLa and Jurkat tumour cell lines. Compound **57** was found to be the most active against the tested cell lines, and the IC_{50} values of **57** observed to be cell lines 0.010 μM , 1.4 μM , and 231.9 μM against HeLa ATCC CRL-1958, Jurkat ATCC TIB-152, and Vero ATCC CCL-81, respectively.⁷⁹

Phosphoglycerate mutase **1** is one of the critical enzymes that supports cancer cell proliferation. Since it regulates




Fig. 9 Structures of anthraquinone analogs reported in the year 2019.



glycolysis and biosynthesis, developing an inhibitor that regulates this enzyme is of therapeutic importance. In this study, Huang *et al.* synthesized anthraquinone derivatives and established the structure–activity relationship (SAR) of the 31 compounds synthesized. Compound **58** was the most effective, with an IC_{50} value of $0.27 \mu M$. It also exhibited antiproliferative activity in different cancer cell lines such as H1299, A549, and PC9 with IC_{50} values $6.9 \pm 1.2 \mu M$; $12.7 \pm 2.7 \mu M$ and $13.8 \pm 1.0 \mu M$, respectively. A deep look at SAR evaluation suggested that 3-sulfonamide substituents of the anthraquinone scaffold played a crucial role in determining the potency of the compounds.⁸⁰

Celik *et al.* synthesized anthraquinone derivatives for evaluation of cytotoxicity potential. Further, the density functional theory (DFT) B3LYP method was used to determine the most stable molecular structure. The stable piperazinyl anthraquinone derivative **59** exhibited potential cytotoxicity against the A549 cell line. However, it was found that high doses of the compound were lethal to healthy human cells, while low dose was ineffective in cancer cells.⁸¹ The existing body of research on PGAM1 inhibitor PGMI-004A suggests that anthraquinone regulates the key pathways like glycolysis and serine synthesis, essential for tumour growth. Based on this information, novel anthraquinone derivatives were synthesized to evaluate their PGAM1 inhibiting activity. Of all the compounds synthesized, compound **60** exhibited good PGAM1 inhibiting activity with an IC_{50} value of $0.25 \pm 0.07 \mu M$. It was further tested to evaluate its *in vitro* cytotoxic activity against H1299, A549, and PC9 cell lines and *in vivo* activity in H1299 xenografts models. The experimental results suggested that the efficacy of the compounds containing phenyl substituents was more active than the compound with dimethylamino and morpholine substituents. To further understand the site of binding, the crystal structure of the **60** and PGAM1 complex was evaluated.⁸²

Literature studies suggest that structurally novel sulfonamide derivatives show pronounced antitumour activity. Taking this into account, Awasthi *et al.* synthesized 1-substituted anthraquinone sulfonamide derivatives and tested their cytotoxic, antibacterial, and antifungal properties. Of all the compounds synthesized, compound (**61**) displayed better cytotoxic activity in HeLa cell lines than the reference compound mitoxantrone. Compound **61** arrested the cell cycle progression at G1 and G2 phases. Docking studies between the synthesized compounds and telomeric sequence revealed that all the synthesized compounds could be suitable i-motif inhibitors.⁸³ Another study involved the synthesis of 9,10-anthraquinone hooked piperidine units to evaluate their antiproliferative activity. The synthesized compounds were tested in drug-sensitive human cancer lines HL-60, LoVo, and drug-resistant cancer cell line HL60/MX2, LoVo/Dx. Later, the compounds were also evaluated in BALB/3T3 normal mouse fibroblasts cell lines (selectivity) using cisplatin, mitoxantrone and doxorubicin as reference compounds. Results suggested that all the compounds were effective against drug-resistant cell lines, with 1-(piperidin-1-yl)-9,10-anthraquinone (**62**) being the most potent of all (Fig. 9). Since all the compounds showed strong potency against drug-resistant HL60/MX2 cell line, it was

concluded that piperidine substituted anthraquinone derivatives can be developed as anticancer agents.

2.6 2020–2021

In the last couple of years, several anthraquinone-based compounds were synthesized and investigated for anticancer properties. The specific objective of the study carried out by Li *et al.* was to synthesize emodin anthraquinone derivatives using microwave-assisted one-step process. The synthesized compounds were examined for their antiproliferative activity in cancer cells. Among all the tested compounds, compound **63** exhibited antitumour effect in HCT116 cells, with an IC_{50} value of $108.1 \mu M$ (Fig. 10). Moreover, it displayed good apoptosis induction by G0/G1 cell cycle arrest and increased the reaction oxygen species at an intracellular level.⁸⁴ In another study, Li *et al.* evaluated *S. lycopersici*. Associated with *D. gemmacea* and isolated two new anthraquinone derivatives, alterporriol Y and macrosporin 2-O- α -D-glucopyranoside. Apart from this, few other known compounds like altersolanol B and altersolanol A were also isolated. All the isolated compounds were evaluated for their antitumour activity in various cancer cells. Altersolanol A (**64**) exhibited significant inhibitory activity with IC_{50} values of 9.0 and $7.2 \mu M$ in HCT-116 and MCF-7 cells, respectively. Altersolanol A also showed growth inhibitory activity in Huh7 cancer stem cell-like cells making it a promising candidate for anticancer agents.⁸⁵

Although mitoxantrone is an established anthraquinone analog to treat cancer, its cardiotoxicity and other serious side effects are less desirable. Hence, Oliveira *et al.* synthesized N-alkylated and O-alkylated anthraquinone derivatives to overcome this limitation. The compounds synthesized were evaluated for their antiproliferative activity in MCF-7, HeLa, M059J tumour cells, and GM07492A non-cancerous human cells. Among all the synthesized, compound (**65**) showed the highest cytotoxic activity with IC_{50} values of 13.6 , 14.1 , and $14.8 \mu M$ on MCF-7, HeLa, and M059J cells, respectively.⁸⁶ Another compound from the series also exhibited antitumour activity with a selectivity index of 1.66 in HeLa and 1.87 in MCF-7 cells. Upon evaluating the structure–activity relationship, it was concluded that the cancer cell selectivity was dependant on the lipophilic nature of the substituents at the 1st and 4th positions of anthraquinone.

Anifowose *et al.* synthesized structural analogues of AQ-101 to evaluate the structural activity relationship of the compounds in acute lymphoblastic leukemia (ALL) cells. Among the synthesized compounds, **66** displayed significant cytotoxic activity against the leukemia cell line with an IC_{50} value of $0.74 \mu M$. The biological activity of these compounds was evaluated using WST-8 assay. It was deciphered that the active compound **66** exhibited cytotoxicity through a different mechanism than its reference compound. Unlike the reference compound AQ-101, it up-regulated p53 expression but did not induced MDM2 degradation. The structural evaluation suggested that adding a methylene moiety by replacing the –NH in chloroacetamide group decreased cytotoxic activity but did not subdue the activity.⁸⁷

Since chemotherapy causes several undesirable side effects, the research for new anticancer drugs continues to be a lucrative area of research. In a recent study, Li *et al.* focused on




Fig. 10 Structures of anthraquinone derivatives reported in the year 2020–2021.

synthesizing amide anthraquinone derivatives to target the proteins in cancer cells specifically. Among the compounds synthesized, **67** showed significant efficacy with an IC_{50} value of $17.80 \mu\text{g mL}^{-1}$ in HCT116 cells. Upon evaluating the biological activity, it is found that the synthesized compounds induce tumour cell apoptosis by activation of ROS-JNK, which in turn releases cytochrome C into the cytoplasm. This reaction further sets off the e-cysteine protease pathway.⁸⁸ Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA) models were used to analyze the structure–activity relationship of the compounds. From the studies, it was interpreted that the activity of the compounds greatly depended on the electron-withdrawing capacity of the nitro group at the C-1 position; the higher the electron-withdrawing capacity, the more the inhibitory activity of the compound.

A considerable amount of research has been published on the potential of heteroarene-fused anthraquinones as anti-tumour drugs. In this direction, Tikhomirov *et al.* examined the role of heterocyclic moiety tethered anthraquinones in regulating cancer. They synthesized a series of naphtho[2,3-*f*]indole-3- and anthra[2,3-*b*]thiophene-3-carboxamides that showed anti-cancer activity similar to the reference compound doxorubicin. Among all the compounds, naphtho[2,3-*f*]indole-3-carboxamide (**68**) exhibited anti-proliferative activity with IC_{50} values of $0.5 \pm 0.2 \mu\text{M}$; $0.9 \pm 0.1 \mu\text{M}$; $0.9 \pm 0.2 \mu\text{M}$; $0.9 \pm 0.1 \mu\text{M}$; $0.8 \pm 0.1 \mu\text{M}$ against Capan-1, HCT116, NCI-H460, HL60 and K562 cancer cell lines respectively. The compound **68** also showed better DNA affinity as compared to its furan and thiophene counterparts. From *in vivo* studies, it was concluded that the compound enhanced the lifespan of mice carrying P388 lymphoma transplants hinting at tumour inhibition.⁸⁹ *Selaginella tamariscina* is a traditional Chinese herb used to treat diseases like cancer, diabetes, and hepatitis. Rui Liu *et al.* isolated four new anthraquinone compounds selaginones A, selaginones B, triarylbenzophenone

analogue, selaginbenzophenone B from *S. tamariscina* herb. Among the compounds isolated, compound **69** showed antiproliferative activity against SMMC-7721 and MHCC97-H cell lines with IC_{50} values of 39.8 and 51.5 μM , respectively. The antiproliferative activity was tested using the CCK-8 method.⁹⁰ Lin *et al.* synthesized 13 anthraquinone derivatives and tested them against a known reference compound cisplatin. Among the synthesized derivatives, **70** showed significant cytotoxicity in NTUB1 and PC3 cells with IC_{50} values of $1.51 \pm 0.31 \mu\text{M}$, and $12.78 \pm 1.46 \mu\text{M}$, respectively (Fig. 10). They further established the efficacy of the compounds using autophagy and MTT assays. Compound **70** at 1 and 3 μM concentrations induced DNA damage and triggered apoptosis in NTUB1 cells. The structural evaluation of **70** suggested that the hydroxy group at C-1 significantly enhanced the antiproliferative activity. Simultaneously, replacing the bromo atom in the side chain of C-3 significantly reduced the cytotoxicity.⁹¹

3. Development of target-specific cytotoxic anthraquinone derivatives

Apart from the above discussed year-wise non-target specific literature, the following section highlights the specific enzyme targeting ability of anthraquinone. Targets such as topoisomerases,⁹² telomerase,⁵⁶ protein kinases,⁹³ MMPs,⁹⁴ and DNA⁹⁵ are the major enzymes with which anthraquinones are known to exert their action.

3.1 Topoisomerase inhibitors

Topoisomerases remain an attractive chemotherapeutic drug target for the discovery and development of novel anticancer agents. Different types of topoisomerase enzymes play a crucial role in DNA replication and transcription within the cells. In addition, the enzymes are involved in the relaxation of positive or negatively supercoiled DNA, the introduction of positive or



negative supercoils into the DNA, and catenation or decatenation of circular and linear DNA, which are vital for cell survival. The enzymes are also accountable for regulating cellular processes other than replication and transcription, DNA repair, chromosomal condensation/segregation, and so on.⁹⁶ Type I and type II topoisomerases are the subfamilies of DNA topoisomerases. In general, Type I topoisomerases interrupt DNA topology by creating a transient single-strand DNA break followed by passage of the opposing single strand in duplex DNA using tyrosine residue in the active site to cleave the DNA strand and form a phosphodiester bond. On the other hand, double-stranded breaks are generated by type II topoisomerase using tyrosine residues in the active site.⁹⁷ Functionally, type I topoisomerases are non-ATP-dependent proteins; hence they depend on the intrinsic strain energy of the supercoiled DNA. In contrast, type II topoisomerases are ATP-dependent proteins and possess a DNA-binding domain and ATP-binding domain. Two biochemically and genetically different topoisomerase II (topo II) forms exist in mammals and are named topo II α and topo II β . Topo II α plays a significant role in mitotic processes and is present in only proliferating cells. At the same time, topo II β is present in all the tissues and expressed abundantly in post-mitotic neuronal cells.⁹⁸ Topoisomerase I, II α , and II β are the principal targets for several marketed cancer drugs. Anthracyclines are the derivatives of anthraquinones, which are

the first recognized class of topoisomerase inhibitors used in cancer chemotherapy.⁹⁹ Doxorubicin (9), epirubicin (10), valrubicin (11), daunorubicin (7), and idarubicin (8) are clinically marketed anthracycline derivatives (Fig. 2). Further, emodin (2), a naturally occurring anthraquinone obtained from plants and fungi, inhibits DNA topoisomerase II. It generates DNA double-strand breaks through stabilization of topoisomerase II–DNA cleavage complex, thereby inhibiting ATP hydrolysis.⁹⁷

McKeown *et al.* and Smith *et al.* reported the topoisomerase activity of the alkylamino anthraquinones with their mono-*N*-oxide structures. Almost all the compounds exhibited good anticancer activity and also elevated the levels of topo II α . Compound 71 displayed greater cytotoxicity and inhibited DNA synthesis in the S-phase of the cell cycle and was more active than the marketed drug mitoxantrone (Fig. 11). Though IC₅₀ value of compound 71 is not reported, the molecular modelling investigations demonstrated that the compound could form stable, intercalated complexes with DNA. Other derivatives such as 72 showed similar cytotoxicity as that of mitoxantrone. The compound 72, when bound to DNA, inhibits topoisomerase II. It was found that any diffusion of compound 72 would result in toxicity to cells irrespective of the level of oxygenation. Further, the analogues like 73 (mono-*N*-oxide) and 74 (di-*N*-oxide) are presently in *in vivo* preclinical evaluation to establish their potential role as bio reductive agents in radiotherapy.^{100,101}




Fig. 11 Anthraquinone derivatives effect the activity of topoisomerases.



In addition, two Ru(II) chiral anthraquinone complexes **75** and **76** showed dual inhibition against topo I and II enzymes. The complexes were intercalated with DNA nucleotide base pairs by strong binding affinity.¹⁰² The propylamine oligopyrrole carboxamides linked with anthraquinones revealed promising anticancer activity by inhibiting topoisomerase I to enhance the biological activity of combilexins (**77**).¹⁰³ Alchemix (**78**), a novel alkylating anthraquinone, displayed effective anticancer activity in both *in vitro* and *in vivo* in drug-resistant (doxorubicin and cisplatin) ovarian cancer cells. The molecule specifically inhibited topo II α as compared to topo II β .¹⁰⁴ The anthraquinone derivatives extracted from the roots of *Rubia cordifolia*, **79** and **80** exhibited maximum inhibition of topoisomerase I at 100 μ M concentration.¹⁰⁵ Further, a series of proline derivatives of anthraquinone-2-carboxylic acid displayed good cytotoxic activity against MCF-7 cells. The analogue **81** inhibited the catalytic activity of both topoisomerase I and II at 30 and 60 μ M concentrations, respectively (Fig. 11).¹⁰⁶

3.2 Matrix metalloproteinase (MMP) inhibitors

Matrix metalloproteinases (MMPs) are Zn and Ca-dependent neutral endopeptidases that play a crucial role in the physiological and pathological remodelling of the extracellular matrix.¹⁰⁷ Based on the substrate specificity, MMP enzymes are categorized into five main groups: gelatinases, stromelysins, collagenases, membrane type enzymes, and others. The activity of the MMPs was evaluated in different disease areas like cancer, cardiovascular diseases, atherosclerosis, and arthritis. In cancer, the MMPs are mainly involved in invasion and metastasis.¹⁰⁸ Among different types of MMPs, gelatinase B (MMP-9) has been associated with the invasive stage of carcinomas. MMP-9 destroys extracellular matrix components such as type I and IV collagen, a major component of the membrane.¹⁰⁹

Naturally occurring aloe-emodin (**3**) acts as a potent anti-tumour agent which inhibits MMP9 enzyme. The treatment of **3** with B16-F10 melanoma cell decreased proliferation in a time-dependent manner, with negligible cell toxicity. Anti-metastatic capability of **3** was reported to be involved in induction of cell differentiation, increase in homotypic aggregation, reduction of both cell motility, and shape fickleness. The gelatin-zymographic analysis showed that aloe-emodin inhibits the secretory MMPs in B16-F10 cells. Compared to the untreated sample, the compound reduced 33% of the MMP-9 activity after 48 h, while a 29% reduction in the enzymatic activity occurred after 72 h. In contrast, MMP-2 activity was slightly increased after 48 h and was back to the control value after 72 h of aloe-emodin treatment.¹¹⁰ Further, aloe-emodin inhibited the nuclear translocation and DNA binding of NF- κ B, a crucial transcription factor that controls MMP-2/9 and VEGF gene expression. Aloe-emodin successfully inhibited MMP-2/9 expression at both mRNA as well as protein levels.¹¹¹

3.3 Telomerase inhibitors

Telomerase, a reverse transcriptase enzyme that stabilizes the telomere length and maintains the chromosome integrity, plays a vital role in cellular immortalization. In general, telomerase is expressed in germline cells and highly expressed in cancer cells (85%), whereas in normal somatic cells, the enzyme expression

is not significant.¹¹² When telomerase is repressed or inhibited, the cells can divide only a few times.¹¹³ Due to the differential expression of the telomerase, the enzyme is considered an essential molecular and specific drug target for cancer therapy. The expression of the catalytic subunit of telomerase, such as human telomerase reverse transcriptase (hTERT), seems to be a significant determinant for telomerase activity. In addition, stabilized secondary DNA structures such as G-tetraplexes are also active targets for drugs that bind directly to the telomerase and disrupt the telomere structure.⁵⁶

2,6-Diamidoanthraquinone (**82**) showed promising anti-cancer activity as compared to mitoxantrone (**14**) and also inhibited the telomerase activity with an IC₅₀ value of 0.1 μ M (Fig. 12).¹¹⁴ Anthrax[1,2-*d*]imidazole-6,11-dione tetracyclic analogue (**54**) (NSC749235), a new telomerase inhibitor, exhibited good cytotoxicity against HeLa and A549 cell lines. Further, DNA binding and molecular modelling studies revealed that the analogue targets the potassium form of human telomeric G-quadruplex DNA at micromolar concentrations.⁷⁶ Further, a series of 2,7-diamidoanthraquinone analogues exhibited a better inhibitory effect on telomerase activity, hTERT expression, and cell proliferation. Among all, anthraquinone derivative **83** revealed better telomerase inhibition by activating the expression of hTERT and secreted embryonic alkaline phosphatase levels (SEAP) without affecting the cell proliferation in the range of 1–20 μ M.¹¹⁵ Further, another set of anthra[1,2-*d*]imidazole-6,11-dione derivatives showed promising anticancer activity against all the tested cell lines. Few of the compounds in the series exhibited promising anticancer activity towards NCI-60 panel cell lines. In addition, the analogues **84–86** affected the expression of SEAP without affecting cell proliferation. Also, the compounds selectively repressed the expression of hTERT and inhibited the telomerase activity. It was reported that small sidechain extension might have better cytotoxic effects on PC-3 cells. Among the synthesized, **84**, **85**, and **86** displayed moderate potency against PC-3 cells with IC₅₀ values of 10.3 μ M, >30 μ M and 16 μ M respectively. Similarly, compounds **84**, **85**, and **86** showed IC₅₀ values of <1 μ M against the inhibition of PhTERT-SEAP cells of H1299 in MTT assay. All three compounds showed IC₅₀ at ~100 μ M towards IMR90 cells, and suggesting that they did not affect the growth of normal cells.¹¹⁶ The di-amino substituted anthraquinone derivative (**87**) displayed better telomerase inhibition (43.3%) at a 10 μ M concentration, and the compound also intercalated in the DNA.¹¹⁷ Perry *et al.* synthesized a series of 1,4- and 2,6-di functionalized amido anthracene-9,10-diones and examined their cytotoxicity along with telomerase inhibitory activity. Among the synthesized, piperidine 2, 6-anthraquinone derivative (**88**) and *N,N'*-dimethiodide derivative (**89**) elicited good enzymatic inhibition of telomerase with IC₅₀ values of 4.5 and 9.4 μ M, respectively.¹¹⁸ Huang *et al.* reported the synthesis of 1,5-bisthioanthraquinones and 1,5-bisacyloxanthraquinones and examined their telomerase activity along with the expression of telomerase. The most active compounds **90**, **91**, and **92** exhibited relative secreted embryonic alkaline phosphatase (SEAP) activity at concentrations of 2.8, 2.4, and 1.8 μ M against PhTERT-SEAP (H1299) and PhTERT-SEAP






Fig. 12 Structures of anthraquinone derivatives that target telomerases.

(hTERT-BJ1) cell lines. The 1,5-bisacyloxyanthraquinones (**90**, **91**, **92**) demonstrated good telomerase inhibitory activity and activated hTERT expression without affecting the cell viability (Fig. 12).¹¹⁹

DNA can acquire a range of alternative conformations based on specific sequence motifs and interactions with several proteins. Among these conformations, G-quadruplex structures are a form of non-canonical nucleic acid structures that can form within specific repetitive G-rich DNA or RNA regions.¹²⁰ These G-quadruplex structures are unique and extensively involved in the regulation of several biological processes. In general, G-rich repeat sequences with the capability to form G-quadruplex structures are present and overrepresented in telomeres, transcriptional start sites, and double-strand break sites.¹²¹ The presence of G-quadruplex structures in telomeres is capable of inhibiting the activity of telomerase, an enzyme that is overexpressed in cancer cells.¹²² Hence, targeting the G-quadruplex structure is one of the promising strategies in developing anticancer therapeutics.

Due to the structural diversity and promising therapeutic activity, some of the anthraquinones derivatives are significantly bound and involved in stabilizing G-quadruplex structures. Das and Dutta reported the promising anticancer activity of anthraquinone-based natural compounds like aloe emodin, aloe emodin-8-glucoside, and aloin. Further, the authors

investigated the binding affinity of these compounds against a set of six different quadruplex structures like c-KIT, c-MYC, HUMTEL, BCL-2, KRAS, and VEGF. Among all the examined structures, aloe emodin (**3**) exhibited significant binding affinity, *i.e.* $(2.11 \pm 0.33) \times 10^5 \text{ M}^{-1}$ towards c-KIT as compared to aloe emodin-8-glucoside $((9.70 \pm 0.50) \times 10^5 \text{ M}^{-1})$. In contrast, aloin was not capable of targeting the quadruplex structures.¹²³ In addition, Wang *et al.* reported the G-quadruplex structure stabilization activity of aloe emodin. Aloe emodin reduced the transcription of hTERT gene in the three different breast cancer cell lines such as MDA-MB-453, MDA-MB-231 and MCF-7. The results unveiled that aloe emodin binds and stabilizes the G-quadruplex DNA with a binding affinity of $2.55 \times 10^6 \text{ M}^{-1}$ and subsequently inhibits the enzymatic activity of the telomerase.¹²⁴

In another study, Mei *et al.* reported the synthesis of a ruthenium(II) complex of emodin and the biological activity of the compound against c-myc G4 DNA. The compound showed good binding affinity with c-myc G-quadruplex DNA with binding affinity of $6.7 \pm 0.19 \times 10^4 \text{ mol L}^{-1}$.¹²⁵ Similarly, Elvira *et al.* synthesized nitrogen substituted 1-(3-aminoprop-1-ynyl)-4-hydroxyanthraquinone derivatives and studied their anticancer potential in a panel of cancer cells like MCF-7, U-87 MG, DU-145, SNB-19, and hTERT lung fibroblasts. Further, the molecular binding studies of the synthesized compounds

towards DNA G-quadruplex revealed that almost all the derivatives showed good binding affinities towards DNA motifs.¹²⁶ In yet another research study, 2,6-disubstituted amido anthracene-9,10-dione dimeric distamycin derivatives were designed and synthesized. Among all the synthesized derivatives, the disubstituted anthraquinone with tri-*N*-methylpyrrole side chain (ANTP) was found to be more promising and exhibited good activity towards c-Myc G-quadruplex DNA with a binding affinity of $3.8 \pm 0.01 \times 10^6 \text{ M}^{-1}$.¹²⁷

3.4 Kinase inhibitors

Protein kinases are the enzymes that phosphorylate protein by transferring γ -phosphate group to the protein, whereas phosphatase removes the phosphate group from protein. Phosphorylation is the most common form of reversible post-translational modifications of the protein.¹²⁸ Approximately 50% of all proteins undergo phosphorylation, and specific kinases, as well as phosphatases tightly, control this process. Almost 538 known kinases are identified in the human genome. These kinases maintain cellular functions by switching the protein function on most protein kinases involved in signalling networks that employ phosphorylation, which modulate target protein activities. The kinases are critically involved in almost all cellular processes that promote cell survival, proliferation, metabolism, and migration.¹²⁹ The abnormal expression of kinases leads to oncogenesis and other diseases. Several kinases are identified that are involved in cancer cell signalling pathways, angiogenesis, proliferation, and metastases of various types of cancer.¹³⁰ Due to widespread clinical applications, kinases are considered promising drug targets for anticancer therapeutics.

3-(Azidomethyl)-1,8-dihydroxy-6-methoxy anthracene-9,10-dione (**93**) is a phyto-based emodin derivative isolated from giant knotweed. The compound exhibited potent anticancer activity in both *in vitro* and *in vivo* models (Fig. 13). Further studies revealed that the compound inhibits the overexpression of Her2/neu in lung cancer and breast cancer through

proteasomal degradation of Her2/neu.¹¹⁵ Another study demonstrated that the anthraquinone derivative **94** was more effective compared to emodin. It inhibited cell proliferation and transformation of HER-2/neu, which is overexpressed in human breast cancer cells *via* blocking the tyrosine phosphorylation of p185neu. The IC_{50} of **94** was found to be 17 μM and 1 μM against tyrosine phosphorylation of HER-2/neu and MDA-MB-453 cells, respectively.¹³¹ Further, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu overexpressing breast cancer cells (MDA-MB-361) by 70% in *in vitro* assay along with inhibition of the tumour growth.⁹³ Muto *et al.* reported that emodin extracted from the root and rhizome of *Rheum palmatum* L., induced apoptosis in myeloma cells. In addition, emodin down-regulated the Mcl-1(induced myeloid leukaemia cell differentiation protein), leading to the apoptotic cell death of cancer cells.¹³² Damnacanthal (**95**) is a potent natural anthraquinone molecule that selectively inhibits p56lck tyrosine kinase with an IC_{50} value of 17 nM. Further, the compound also has therapeutic efficacy in treating T-cell malignancies and autoimmune diseases.¹³³ In a separate study, Shi *et al.* isolated several antiproliferative anthraquinone derivatives from *Hedyotis diffusa*. Among the isolated compounds, 2-hydroxy-3-methylantraquinone (**96**) induced apoptotic mediated cell death in malignant cells *via* mitochondrial pathway by inhibiting receptor Src tyrosine kinase. Compound **96** displayed IC_{50} values of 33 μM and 67 μM against protein tyrosine kinases activities of pp60-src (3 U mL^{-1}), active GST-v-src protein (0.1 mg mL^{-1}) and natural SPCA-1 cell lysate (0.5 mg mL^{-1}) prepared as target proteins. Further, compound **96** exhibited an IC_{50} value of 51 μM against HepG-2 cell lines.¹³⁴ 1-Deoxy-rhodoptilometrin (**97**), another anthraquinone derivative, is a marine metabolite described to act as a potential lead for anticancer activity by inhibiting various distinct protein kinases such as EGFR, ERBB-2,4 and IGF-1. Compound **97** showed inhibitory activity against 23 protein kinases and was found to be the most potent inhibitor of Aurora-A, Aurora-B, EGF-R, SRC,




Fig. 13 Anthraquinone derivatives targeting kinases involved in cancer progression.



and VEGF-R2 at IC_{50} of 3, 1.8, 4, 3.7, and 1.8 μ M, respectively.¹³⁵ Similarly, quinalizarin (**98**), a potent kinase inhibitor, possessed the ability to selectively inhibit CK2 (Ser/Thr protein kinase) comparable to emodin. It induced apoptosis more effectively than other CK2 inhibitors, which are commonly used like 4,5,6,7-tetra bromo-1*H*-benzotriazole and 2-dimethylamino-4,5,6,7-tetra bromo-1*H*-benzimidazole (Fig. 13). The IC_{50} value of quinalizarin was found to be 0.11 μ M inhibiting HEK-293T cells. Jurkat cells upon treatment with compound **98** (5 μ M) for 4 h treatment showed a 48% fall in CK2 activity in the cell lysates. Compound **98** (quinalizarin) is structurally very similar to emodin, a quite promiscuous inhibitor of CK2 and of several other protein kinases as well. It exhibited potency toward PIM3 (IC_{50} of 0.08 μ M) that is 30-fold higher than that of CK2 (IC_{50} of 2.50 μ M).¹³⁶

3.5 Miscellaneous cancer targets

Ecto-nucleotidases are the enzymes that hydrolyse the extracellular nucleotides to nucleosides and control nucleoside (P1) and nucleotide (P2) receptor-mediated signaling.¹³⁷ The enzyme alters the adenosine level that in turn increases or decreases P1 and P2 receptor activity. Hence, the inhibition of adenosine production in the tumour cell environment, through inhibiting the enzyme activity, might be a promising and novel strategy for anticancer therapy.^{138,139} Baqi Y reported that some of the anthraquinone derivatives **99** and **100** were found to be potent inhibitors of ecto-nucleotidase with inhibitory constant (K_i) values of 150 and 260 nM, respectively (Fig. 14).¹⁴⁰ Similarly, physcion (**101**), a naturally occurring anthraquinone derivative, is a promising anticancer agent primarily used to treat human nasopharyngeal cancer. It induced apoptosis and autophagy in human nasopharyngeal cancer cells by the downregulation of transcription factor Sp1. Compound **101**, also known as parietin, upon treatment with physcion (5, 10, and 20 μ mol L^{-1}) in a dose-dependent manner suppressed the cell viability and colony formation in CNE2 cells. Physcion (10 and 20 μ mol L^{-1}) dose-dependently blocked cell cycle progression at G1 phase

and induced both caspase-dependent apoptosis and autophagy in CNE2 cells. Similarly, **101** induced apoptosis and autophagy in human nasopharyngeal carcinoma cells by targeting Sp1, which was mediated by ROS/miR-27a/ZBTB10 signaling.¹⁴¹

Apart from the mentioned targets, emodin exhibited selective activity towards human nasopharyngeal cancer cells (CNE-2Z). It reduced cell viability and induced cell cycle arrest and apoptotic cell death by targeting the chloride channels in CNE-2Z cells compared to positive control tamoxifen.¹⁴² In addition, emodin exhibited an anti-metastatic effect by the down-regulation of CXC chemokine receptor type 4. The CXC chemokine receptor type 4 plays a crucial role in cancer invasion and metastasis.¹⁴³ Furthermore, emodin also inhibited Vascular Endothelial Growth Factor Receptor (VEGFR) and MMPs in connotation with downregulation of runt-related transcription factor 2 (Runx2), which controls both VEGF signalling and transcriptional activity.¹⁴⁴ Further, emodin has a structural similarity with ATP Citrate Lyase (ACL) inhibitors. ACL plays a significant role in *de novo* fatty acid and cholesterol biosynthesis. Moreover, the enzyme is highly expressed in some of the cancer cells. Hence it can act as a promising anticancer agent by inhibiting the ACL enzyme.¹⁴⁵

Another naturally occurring anthraquinone **102**, isolated from endophytic fungi, was reported as an anticancer agent that induced caspase-mediated apoptosis and also suppressed phosphorylation of Akt kinase. Compound **102** displayed activation of caspases (8, 9 and 3) and poly (ADP-ribose) polymerase (PARP) in MCF-7 and MDA-MB-435 breast cancer cells significantly at concentrations of 3.75 μ M and 3 μ M, respectively.¹⁴⁶ Similarly, Kamiya *et al.* isolated ten anthraquinones from *Morinda citrifolia* roots and examined their anticancer potential against human colon cancer (HCT116) cells and DNA polymerase activity. One of the compounds, morindone (**103**), showed significant polymerase inhibition properties, thereby suppressing the growth of HCT116 cells. It induced cell growth suppression with LD_{50} value 32.2 μ M on human DNA polymerase γ .¹⁴⁷ Finally, the sulphonamide-anthraquinone




Fig. 14 Anthraquinone derivatives that target other miscellaneous proteins involved in cancer growth.

derivative **104** was reported to inhibit cancer cell progression in several types of cancer cells. It significantly inhibited the proliferation of HCT116, HCT116 p53^{−/−} and p53 mutant HT29 (R273H) cells at a level comparable to that of the positive control 5-FU (10 μM) in MTT assay. The derivative **104** induced cell cycle arrest at the S and G2/M phases (38.5, 42.2, and 33.4; 28.1, 29.5, and 49.0%, respectively) compared to that induced by the vehicle control (30.2, 36.3 and 21.2; 23.4, 27.1, and 20.5%, respectively). Treatment with 10 μM of **104** increased caspase-3 cleavage in all three cell lines (HCT116, HCT116 P53^{−/−} and HT29). These results indicated that **104** induced both apoptotic and necrotic cell death in a p53-independent manner (Fig. 14).¹⁴⁸

4. Toxicity of anthraquinones

Toxicity or safety assessment of a potential drug molecule is the primary area of concern before clinical usage.¹⁴⁹ Apart from the favourable pharmaceutical applications, some anthraquinone derivatives may induce potential damage to cells due to their close resemblance to anthracene, a toxic analogue.¹⁵⁰ A few *in vitro* studies describe the toxicity behavior of anthraquinone derivatives with limited information on *in vivo* studies of anthraquinones. Liu *et al.* investigated the *in vitro* and *in silico* hepatotoxicity of different anthraquinones and their derivatives. Among all the studied, rhein was identified as a potential liver toxicant against HuH-7 cells with an EC₅₀ value of 93.9 μM upon repeated treatment.¹⁵¹ Chen *et al.* examined the photoinduced acute toxicity of a series of fourteen anthraquinone derivatives against *Daphnia magna*, an important model organism for toxicity assessment. Almost all the compounds exhibited no observable toxicity in the presence of visible light at the maximum concentration of the compounds used in the study. However, chloro and dihydroxy substituted anthraquinones exhibited apparent toxicity in presence of visible light with EC₅₀ values of 837.0 and 959.3 nmol L^{−1}, respectively.¹⁵²

Further, Viljoen *et al.* summarized the toxicity of emodin against mouse and rat fetuses. The study revealed that emodin displayed adverse effects against mice and rats at 17 and 60 mg kg^{−1} or higher doses. In addition, emodin was noticed to be toxic towards brine shrimp and exhibited lethality with an LC₅₀ value of 0.19 μM .¹⁵³ Oshida *et al.* examined the toxicological effects of emodin on differential gene expression profiles of the testis in mice models. The compound producing testicular toxicity in male mouse models *via* IGF-1 receptor signalling pathway.¹⁵⁴ He *et al.* investigated the potential toxicity effects of emodin on zebrafish embryos. The compound displayed adverse effects on embryo survival as well as hatching success in zebrafish at a concentration of 0.93 μM and higher. In addition to this, it induced many abnormalities in zebrafish embryos, including oedema, abnormal morphogenesis, and crooked trunk.¹⁵⁵

Anthraquinones present in plant species such as *Rhamnus* species (aloe-emodin, physcion, rhein, chrysophanol, emodin) were suspected to be involved in diseases such as renal failure, rhabdomyolysis, nephrotoxicity (regular intake), dehydration, anorexia (long-term exposure), genotoxicity in mammalian

cells, mutation, tumour promotion, chromosomal aberration and liver enlargement. In addition to this, the long-term use of anthranoid laxatives is reported to exhibit symptoms associated with melanosis coli which is characterized by dark pigmentation of the colonic mucosa, and in few cases, it is also believed to result in morphological changes of the colonic myenteric system.¹⁵⁶ This is because anthraquinone-based drugs contain chromophores which impart a bright yellow colour to colonic epithelial cells and is reversible in most of cases. However, they are also suspected to cause permanent physical change to colonic tissue as well as permanent damage of renal tubular cells resulting in more serious conditions such as Chron's disease or ulcerative colitis.

The anthraquinone derivatives, especially those derived from Rhubarb have shown neuroprotective effects. Emodin exerted a neuroprotective effect in cerebral ischemic stroke (CIS) by maintaining the integrity of blood–brain barrier (BBB), ameliorating inflammation, and controlling the apoptosis process. Li *et al.* attributed this effect of emodin to the inhibition of connexin 43 (Cx43) and aquaporin 4 (AQP4).¹⁵⁷ The neuroprotective effect of chrysophanol (CHR) was reported to be associated with oxidative/antioxidative, anti-inflammatory and by inhibiting apoptosis. Similarly, Zhao *et al.* reported neuroprotective effect of rhein is by oxidative stress and apoptosis.¹⁵⁸

5. Polyethylene glycol (PEG) based anthraquinone drug delivery

Anthraquinones are one of the key chemotherapeutic agents used in the early management of cancer. Anthraquinones are potent anti-cancer agents with many beneficial effects; however, few unwanted properties such as low polarity and structural instability in *in vivo* conditions are also observed in some cases. Current research studies mainly focus on enhancing the biological efficacy of naturally occurring and chemically synthesized anthraquinone derivatives. However, few drug delivery approaches are reported to address the undesired properties of low polarity and stability. It is imperative to develop drug delivery vehicles for anthraquinone or build multi-drug delivery systems to administer two or three anti-cancer agents in one dose. Polymer based control release formulations are gaining importance as they are very efficient in loading multiple drugs in layers for attaining programmed release kinetics under *in vivo* conditions.¹⁵⁹ One such example was a report where a DNA-damaging anthracycline agent doxorubicin (dox) (**10**) and a phosphatidylinositol-3 kinase inhibitor wortmannin (wor) were conjugated. These drugs were used alone or in combination with poly(ethylene glycol)-poly(aspartate hydrazide) block copolymers through a hydrazone bond.¹⁶⁰ The polymer formed unimodal micelle structure encapsulating the conjugated anti-cancer drugs (dox and wor). The polymer-drug conjugated system developed in this way has particle size of <100 nm. The drug mixing ratios between dox/wor were precisely controlled in this delivery system. This polymer-drug conjugated system reported better drug release properties and also reduced the



amount of drug (wor) required for cytotoxicity while maintaining the biological activity of the independent polymeric micelles.

Other PEG conjugated systems reported in recent literature include poly(ethylene glycol) PEG-doxorubicin (dox) conjugates with polymers of linear or branched architecture (molecular weight 5000–20 000 g mol⁻¹), and different peptidyl linkers (GFLG, GLFG, GLG, GGRR, and RGLG). GFLG linker showed ~30% release of dox at 5 h irrespective of PEG molecular weight or architecture. All PEG conjugates prepared by this method were more than 10-fold less toxic (IC₅₀ values >2 µg mL⁻¹) than free Dox (IC₅₀ value of 0.24 µg mL⁻¹). PEG-dox showed greater tumour-targeting than free Dox in radiolabelled studies. The radio iodinated PEGs showed a clear relationship between molecular weight, blood clearance, and tumour accumulation.¹⁶¹

Other more advanced conjugate systems of anthraquinones reported in the literature are polymer enzyme liposome therapy (PELT),¹⁶² triple block nanocarrier (TBN) platforms,¹⁶³ and amphiphilic core cross-linked star (CCS) polymers¹⁶⁴ that showed excellent pharmacokinetic profile in *in vivo* models. In a TBN platform, hydrophilic polyethylene glycol (PEG) was used as an outer shell, and a hydrophobic biodegradable polycaprolactone (PCL) block for encapsulating anthracycline anti-cancer drug was utilized as the middle layer. The carboxylic-functionalized polycaprolactone (CPCL) based inner shell was filled with non-anthracycline anti-cancer drug for inducing synergistic effect. The dual drug-loaded TBN exhibited superior synergistic cell death at much lower drug concentrations.¹⁶³

These findings represent the critical role of PEG-conjugated anthracycline-based effective anti-cancer drug delivery methodology that might reduce the effective dose and toxicity *in vivo* compared to the conventional drug formulations.

6. Structure–activity relationship of anthraquinones

Structure–activity relationship (SAR) studies of the anthraquinone ring structure provide an idea about the primary structural considerations that result in maximum biological effect. Moreover, it is essential to assess the substituents which undergo enzymatic degradation due to endogenous enzymes, thereby eliminating the molecule before it exerts its activity. SAR studies help understand the groups that improve the synthesized molecule's pharmacokinetics and substituents resistant to enzymatic degradation. Few of the SAR observations are discussed here.

Studies showed that the sulphonamide and methyl ketone substituent at 1st position of anthraquinone would be advantageous in exerting superior anticancer activity. Similarly, carboxylic acid substitution at 1st position would result in activity loss.⁶³ Another report suggested that when anthraquinone monomers are considered, the position of hydroxyl (C-5 and C-8) is very crucial for antitumour efficacy. The hydroxylation at the C-1 position was reported to drastically enhance its cytotoxic activity, which indicates that the phenolic hydroxyl

groups are essential for the antitumour activity of anthraquinones.¹⁶⁵ Emodin is identified as the most abundantly existing anthraquinone in plant species having a wide range of anti-cancer properties on various cancers. Dong *et al.* identified that C-1 and C-3 are the most important functional sites for anti-tumour activities of anthraquinone molecules.⁵⁰ Zhou *et al.* reported six anthraquinones from *Xanthophyllum atropvensis pierre* and studies revealed that a large steric hindrance due to glycosyl substituents was the reason for the weakening of the bond between drug and target cells. The substituents such as hydroxyl or hydroxymethyl groups present at only the C-1 position, then the anthraquinones exhibit similar cytotoxic activity. In one of the comparative studies between emodin (anthraquinone) and cassiamin (bianthraquinones), bianthraquinones showed lower anti-cancer activities than anthraquinones, and the reason ascribed to this observation was the steric hindrance of bianthraquinones with a distorted confirmation.¹⁶⁶ Additionally, the atomic charge at C-10 position and the number of hydroxyl groups present on the benzene ring of monomer increased its anti-cancer potency compared to its dimer. Similarly, chlorination was found to decrease the efficacy of these compounds.¹⁶⁷

7. Future perspectives & conclusion

Cancer, characterized by unbridled cell proliferation, is a leading cause of death because of high incidence and mortality, which is exacerbated by the emergence of drug resistance. Therefore, there is a need for the development of new anticancer agents. Anthraquinones have attracted the medicinal chemist's attention for their diverse biological potential. They are typical anticancer fragments that have a broad scope for chemical modifications to be exploited to develop new anticancer agents. A handful of anticancer drugs based on anthraquinone moiety are marketed and used in chemotherapy in stand-alone regimens or widely used in combination therapy alongside radiation treatment to mitigate the metastasis of cancer cells. However, the emergence of resistance is increasingly being reported, and new explorations were undertaken to develop new anthraquinone-based anticancer agents with some success.

Unfortunately, the majority of the research being pursued in academia, leading to the generation of a library of anthraquinones, is not intensively explored towards understanding their mechanistic biological pathways and target-specific activity in *in vitro* and *in vivo* models. Moreover, the toxicity and safety assessment of the anthraquinone derivatives to be used as potential drug molecules needs to be thoroughly investigated at the academic research level as limited research is available in the public domain. The toxicity and efficacy studies such as pharmacokinetics and pharmacodynamics could help better understand the profile of new anthraquinones. Hence, it is highly desirable to explore the potential of these anthraquinone libraries to identify hit/lead-like molecules that can be taken up for further development.

Several opportunities are ready to be fully exploited, which include selective drug delivery, combination with other



anticancer drugs, computational techniques (e.g., ligand-based drug designing), drug repurposing, etc. Some of the issues critical to few anthraquinone derivatives, such as low polarity and structural instability in *in vivo* conditions, could be successfully addressed by employing polyethylene glycol-based drug delivery vehicles. There is ample scope for utilizing anthraquinone-based anticancer drugs in combination therapies with newly approved anticancer drugs targeting different biological receptors. This can be achieved through a detailed understanding of the mechanistic pathways of the intended combination. The development of modern age tools and computational techniques such as ligand-based drug designing (LBDD) and scaffold hopping led to newer molecules with improved efficacies. The *in silico* drug designing tools tremendously boosted the field of anthraquinone-anticancer drug discovery in the diversification of targets, from kinases to genes and immune responses. By leveraging the new age bio/cheminformatics tools, one can design anthraquinone-based new chemical entities with much accuracy in terms of safety & efficacy. Further, the emergence of drug repurposing techniques could be utilized to explore this scaffold for new therapeutic applications, and there is development in this direction, as can be construed from literature.

In view of the ongoing challenge of drug resistance of the existing marketed drugs, concerted efforts are required to address the shortcomings in academia research (limited advanced studies) and utilize the aforementioned approaches. This could lead to the development of new anthraquinone-based anticancer agents that can eventually be translated into safer and effective chemotherapeutics.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors are grateful to the Deanship of the Scientific Research (DSR), Umm Al-Qura University, for the financial support through the project code: 19-SCI-1-01-0019.

References

- H. Hussain, A. Al-Harrasi, A. Al-Rawahi, I. R. Green, R. Csuk, I. Ahmed, A. Shah, G. Abbas, N. U. Rehman and R. Ullah, *Expert Opin. Ther. Pat.*, 2015, **25**, 1053–1064.
- W. Tian, C. Wang, D. Li and H. Hou, *Future Med. Chem.*, 2020, **12**, 627–644.
- Demsiben, *Justus Liebig's Ann. Chem.*, 1840, **34**, 287–296.
- C. Graebe, *Ber. Dtsch. Chem. Ges.*, 1890, **23**, 3739–3740.
- M. Phillips, *Chem. Rev.*, 1929, **6**, 157–174.
- C. Graebe and C. Liebermann, *Ber. Dtsch. Chem. Ges.*, 1869, **2**, 14.
- R. Fittig, *Ber. Dtsch. Chem. Ges.*, 1873, **6**, 167–169.
- A. R. Burnett and R. H. Thomson, *J. Chem. Soc. C*, 1967, 2100–2104, DOI: 10.1039/J39670002100.
- R. Singh and S. M. Chauhan, *Chem. Biodiversity*, 2004, **1**, 1241–1264.
- M. Klaper, P. Wessig and T. Linker, *Chem. Commun.*, 2016, **52**, 1210–1213.
- J. J. Dong, D. Unjaroen, F. Mecozzi, E. C. Harvey, P. Saisaha, D. Pijper, J. W. deBoer, P. Alsters, B. L. Feringa and W. R. Browne, *ChemSusChem*, 2013, **6**, 1774–1778.
- Y. Xu, Z. Yang, J. Hu and J. Yan, *Synthesis*, 2013, **45**, 370–374.
- R. Kumar, N. Sharma, N. Sharma, A. Sharma and A. K. Sinha, *Mol. Diversity*, 2011, **15**, 687–695.
- S. El-Sayrafi and S. Rayyan, *Molecules*, 2001, **6**, 279–286.
- H. Kaper, M. Antonietti and F. Goettmann, *Tetrahedron Lett.*, 2008, **49**, 4546–4549.
- M. N. Akhtar, S. Zareen, S. K. Yeap, W. Y. Ho, K. M. Lo, A. Hasan and N. B. Alitheen, *Molecules*, 2013, **18**, 10042–10055.
- X. Wang and V. Snieckus, *Synlett*, 1990, **1990**, 313–316.
- T. Sawano, Y. Toyoshima and R. Takeuchi, *Inorganics*, 2019, **7**(11), 138.
- T. J. Monks, R. P. Hanzlik, G. M. Cohen, D. Ross and D. G. Graham, *Toxicol. Appl. Pharmacol.*, 1992, **112**, 2–16.
- E. M. Malik and C. E. Müller, *Med. Res. Rev.*, 2016, **36**, 705–748.
- Y. Caro, L. Anamale, M. Fouillaud, P. Laurent, T. Petit and L. Dufosse, *Nat. Prod. Bioprospect.*, 2012, **2**, 174–193.
- D. W. Shaw, *Dermatitis*, 2009, **20**, 292–295.
- L. Dufossé, *Food Res. Int.*, 2014, **65**, 132–136.
- E. M. Malik, Y. Baqi and C. E. Müller, *Beilstein J. Org. Chem.*, 2015, **11**, 2326–2333.
- T. Furuta, Y. Hirayama and M. Iwamura, *Org. Lett.*, 2001, **3**, 1809–1812.
- S. Patnaik, A. Swami, D. Sethi, A. Pathak, B. S. Garg, K. C. Gupta and P. Kumar, *Bioconjugate Chem.*, 2007, **18**, 8–12.
- J. C. Forti, R. S. Rocha, M. R. V. Lanza and R. Bertazzoli, *J. Electroanal. Chem.*, 2007, **601**, 63–67.
- M. Uchimiya and A. T. Stone, *Chemosphere*, 2009, **77**, 451–458.
- G. Rath, M. Ndonzao and K. Hostettmann, *Int. J. Pharmacogn.*, 1995, **33**, 107–114.
- D. L. Barnard, D. W. Fairbairn, K. L. O'Neill, T. L. Gage and R. W. Sidwell, *Antiviral Res.*, 1995, **28**, 317–329.
- R. F. Schinazi, C. K. Chu, J. R. Babu, B. J. Oswald, V. Saalman, D. L. Cannon, B. F. Eriksson and M. Nasr, *Antiviral Res.*, 1990, **13**, 265–272.
- D. O. Andersen, N. D. Weber, S. G. Wood, B. G. Hughes, B. K. Murray and J. A. North, *Antiviral Res.*, 1991, **16**, 185–196.
- C. P. Osman, N. H. Ismail, R. Ahmad, N. Ahmat, K. Awang and F. M. Jaafar, *Molecules*, 2010, **15**, 7218–7226.
- M. Y. Fosso, K. Y. Chan, R. Gregory and C. W. Chang, *ACS Comb. Sci.*, 2012, **14**, 231–235.
- W. Wang, R. Chen, Z. Luo, W. Wang and J. Chen, *Nat. Prod. Res.*, 2018, **32**, 558–563.



- 36 K. H. Gan, C. H. Teng, H. C. Lin, K. T. Chen, Y. C. Chen, M. F. Hsu, J. P. Wang, C. M. Teng and C. N. Lin, *Biol. Pharm. Bull.*, 2008, **31**, 1547–1551.
- 37 S. Z. Choi, S. O. Lee, K. U. Jang, S. H. Chung, S. H. Park, H. C. Kang, E. Y. Yang, H. J. Cho and K. R. Lee, *Arch. Pharmacol. Res.*, 2005, **28**, 1027–1030.
- 38 A. Arvindekar, T. More, P. V. Payghan, K. Laddha, N. Ghoshal and A. Arvindekar, *Food Funct.*, 2015, **6**, 2693–2700.
- 39 T. C. Jackson, J. D. Verrier and P. M. Kochanek, *Cell Death Dis.*, 2013, **4**, e451.
- 40 B. A. van Gorkom, E. G. de Vries, A. Karrenbeld and J. H. Kleibeuker, *Aliment. Pharmacol. Ther.*, 1999, **13**, 443–452.
- 41 A. M. Alaadin, E. H. Al-Khateeb and A. K. Jäger, *Pharm. Biol.*, 2007, **45**, 688–690.
- 42 Y. Baqi, K. Atzler, M. Köse, M. Glänzel and C. E. Müller, *J. Med. Chem.*, 2009, **52**, 3784–3793.
- 43 R. W. Winter, K. A. Cornell, L. L. Johnson, L. M. Isabelle, D. J. Hinrichs and M. K. Riscoe, *Bioorg. Med. Chem. Lett.*, 1995, **5**, 1927–1932.
- 44 E. M. Perchellet, M. J. Magill, X. Huang, D. M. Dalke, D. H. Hua and J. P. Perchellet, *Anti-Cancer Drugs*, 2000, **11**, 339–352.
- 45 M. B. Martins-Teixeira and I. Carvalho, *ChemMedChem*, 2020, **15**, 933–948.
- 46 Y. Lazebnik, *Nat. Rev. Cancer*, 2010, **10**, 232–233.
- 47 L. A. Torre, R. L. Siegel, E. M. Ward and A. Jemal, *Cancer Epidemiol., Biomarkers Prev.*, 2016, **25**, 16–27.
- 48 D. Wang, X.-H. Wang, X. Yu, F. Cao, X. Cai, P. Chen, M. Li, Y. Feng, H. Li and X. Wang, *Front. Pharmacol.*, 2021, **12**, 638993.
- 49 W. Wu, N. Hu, Q. Zhang, Y. Li, P. Li, R. Yan and Y. Wang, *Chem.-Biol. Interact.*, 2014, **219**, 18–27.
- 50 X. Dong, J. Fu, X. Yin, S. Cao, X. Li, L. Lin and J. Ni, *Phytother. Res.*, 2016, **30**, 1207–1218.
- 51 S. Siddamurthi, G. Gutti, S. Jana, A. Kumar and S. K. Singh, *Future Med. Chem.*, 2020, **12**, 1037–1069.
- 52 C. H. Teng, S. J. Won and C. N. Lin, *Bioorg. Med. Chem.*, 2005, **13**, 3439–3445.
- 53 M. Siwy, D. Sek, B. Kaczmarczyk, I. Jaroszewicz, A. Nasulewicz, M. Pelczyńska, D. Nevozhay and A. Opolski, *J. Med. Chem.*, 2006, **49**, 806–810.
- 54 J. A. Valderrama, O. Espinoza, M. F. González, R. A. Tapia, J. A. Rodríguez, C. Theoduloz and G. Schmeda-Hirschmann, *Tetrahedron*, 2006, **62**, 2631–2638.
- 55 L. F. Tietze, K. M. Gericke and I. Schuberth, *Eur. J. Org. Chem.*, 2007, **2007**, 4563–4577.
- 56 H. S. Huang, K. F. Huang, C. L. Li, Y. Y. Huang, Y. H. Chiang, F. C. Huang and J. J. Lin, *Bioorg. Med. Chem.*, 2008, **16**, 6976–6986.
- 57 S. Wang, Q. Wang, Y. Wang, L. Liu, X. Weng, G. Li, X. Zhang and X. Zhou, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 6505–6508.
- 58 Z. Yang, J.-A. Kang, W.-H. Kim, A.-Y. Park, H.-S. Kim, J.-S. Kim, J.-A. Kim, P. Gong, L.-S. Jeong and H.-R. Moon, *Bull. Korean Chem. Soc.*, 2009, **30**, 1463–1469.
- 59 G. Z. Jin, H. S. Jin and L. L. Jin, *Arch. Pharmacol. Res.*, 2011, **34**, 1071–1076.
- 60 H. Y. Tu, A. M. Huang, C. H. Teng, T. C. Hour, S. C. Yang, Y. S. Pu and C. N. Lin, *Bioorg. Med. Chem.*, 2011, **19**, 5670–5678.
- 61 S. X. Feng, Q. Guan, T. Chen and C. Du, *Arch. Pharmacol. Res.*, 2012, **35**, 1251–1258.
- 62 V. Marković, A. Janićijević, T. Stanojković, B. Kolundžija, D. Sladić, M. Vujčić, B. Janović, L. Joksović, P. T. Djurdjević, N. Todorović, S. Trifunović and M. D. Joksović, *Eur. J. Med. Chem.*, 2013, **64**, 228–238.
- 63 D. Bhasin, J. P. Etter, S. N. Chettiar, M. Mok and P. K. Li, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 6864–6867.
- 64 V. Castro-Castillo, C. Suárez-Rozas, N. Castro-Loiza, C. Theoduloz and B. K. Cassels, *Eur. J. Med. Chem.*, 2013, **62**, 688–692.
- 65 Y. R. Lee, D. S. Yu, Y. C. Liang, K. F. Huang, S. J. Chou, T. C. Chen, C. C. Lee, C. L. Chen, S. H. Chiou and H. S. Huang, *PLoS One*, 2013, **8**, e56284.
- 66 Z. Liang, J. Ai, X. Ding, X. Peng, D. Zhang, R. Zhang, Y. Wang, F. Liu, M. Zheng, H. Jiang, H. Liu, M. Geng and C. Luo, *ACS Med. Chem. Lett.*, 2013, **4**, 408–413.
- 67 A. T. Taher and G. H. Hegazy, *Arch. Pharmacol. Res.*, 2013, **36**, 573–578.
- 68 B. Kolundžija, V. Marković, T. Stanojković, L. Joksović, I. Matić, N. Todorović, M. Nikolić and M. D. Joksović, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 65–71.
- 69 M. S. Almutairi, G. H. Hegazy, M. E. Haiba, H. I. Ali, N. M. Khalifa and M. Soliman Ael, *Int. J. Mol. Sci.*, 2014, **15**, 22580–22603.
- 70 Y. W. Chen, H. S. Huang, Y. S. Shieh, K. H. Ma, S. H. Huang, D. Y. Hueng, H. K. Sytwu and G. J. Lin, *PLoS One*, 2014, **9**, e104703.
- 71 S. Sangthong, N. Sangphech, T. Palaga, N. Ngamrojanavanich, S. Puthong, T. Vilaivan and N. Muangsinsin, *Eur. J. Med. Chem.*, 2014, **77**, 334–342.
- 72 P.-Z. Zhang, H.-L. Yang, C.-C. Li, Z.-C. Xia, X.-M. Wang, H. Wei, R.-X. Rong, Z.-R. Cao, K.-R. Wang, H. Chen and X.-L. Li, *Chin. Chem. Lett.*, 2014, **25**, 1057–1059.
- 73 L. Kelland, *Idrugs*, 1998, **1**, 397–398.
- 74 I. Zuravka, A. Sosic, B. Gatto and R. Göttlich, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 4606–4609.
- 75 F. Prati, C. Bergamini, M. T. Molina, F. Falchi, A. Cavalli, M. Kaiser, R. Brun, R. Fato and M. L. Bolognesi, *J. Med. Chem.*, 2015, **58**, 6422–6434.
- 76 Y. H. Lin, S. M. Chuang, P. C. Wu, C. L. Chen, S. Jeyachandran, S. C. Lo, H. S. Huang and M. H. Hou, *Sci. Rep.*, 2016, **6**, 31019.
- 77 Y. Zheng, L. Zhu, L. Fan, W. Zhao, J. Wang, X. Hao, Y. Zhu, X. Hu, Y. Yuan, J. Shao and W. Wang, *Eur. J. Med. Chem.*, 2017, **125**, 902–913.
- 78 N. Okumura, H. Mizutani, T. Ishihama, M. Ito, A. Hashibe, T. Nakayama and B. Uno, *Chem. Pharm. Bull.*, 2019, **67**, 717–720.
- 79 V. C. Roa-Linares, Y. Miranda-Brand, V. Tangarife-Castaño, R. Ochoa, P. A. García, M. Castro, L. Betancur-Galvis and A. San Feliciano, *Molecules*, 2019, **24**, 1279.



- 80 K. Huang, L. Jiang, H. Li, D. Ye and L. Zhou, *Molecules*, 2019, **24**, 806.
- 81 S. Celik, F. Ozkok, A. E. Ozel, Y. Müge Sahin, S. Akyuz, B. D. Sigirci, B. B. Kahraman, H. Darici and E. Karaoz, *J. Biomol. Struct. Dyn.*, 2020, **38**, 756–770.
- 82 K. Huang, L. Jiang, R. Liang, H. Li, X. Ruan, C. Shan, D. Ye and L. Zhou, *Eur. J. Med. Chem.*, 2019, **168**, 45–57.
- 83 P. Awasthi, M. Vatsal and A. Sharma, *J. Biomol. Struct. Dyn.*, 2019, **37**, 4465–4480.
- 84 Y. Li, F. Guo, T. Chen, L. Zhang, Z. Wang, Q. Su and L. Feng, *Chem. Biodiversity*, 2020, **17**, e2000328.
- 85 J. Li, Y. B. Zheng, T. Kurtán, M. X. Liu, H. Tang, C. L. Zhuang and W. Zhang, *Nat. Prod. Res.*, 2020, **34**, 2116–2123.
- 86 L. A. Oliveira, H. D. Nicolella, R. A. Furtado, N. M. Lima, D. C. Tavares, T. A. Corrêa and M. V. Almeida, *Med. Chem. Res.*, 2020, **29**, 1611–1620.
- 87 A. Anifowose, A. A. Agbowuro, R. Tripathi, W. Lu, C. Tan, X. Yang and B. Wang, *Med. Chem. Res.*, 2020, **29**, 1199–1210.
- 88 Y. Li, F. Guo, Y. Guan, T. Chen, K. Ma, L. Zhang, Z. Wang, Q. Su, L. Feng, Y. Liu and Y. Zhou, *Molecules*, 2020, **25**, 1672.
- 89 A. S. Tikhomirov, V. A. Litvinova, D. V. Andreeva, V. B. Tsvetkov, L. G. Dezhenkova, Y. L. Volodina, D. N. Kaluzhny, I. D. Treshalin, D. Schols, A. A. Ramonova, M. M. Moisenovich, A. A. Shtil and A. E. Shchekotikhin, *Eur. J. Med. Chem.*, 2020, **199**, 112294.
- 90 R. Liu, H. Zou, Z. X. Zou, F. Cheng, X. Yu, P. S. Xu, X. M. Li, D. Li, K. P. Xu and G. S. Tan, *Nat. Prod. Res.*, 2020, **34**, 2709–2714.
- 91 K. W. Lin, W. H. Lin, C. L. Su, H. Y. Hsu and C. N. Lin, *Bioorg. Chem.*, 2021, **107**, 104395.
- 92 Y. Li, Y. Luan, X. Qi, M. Li, L. Gong, X. Xue, X. Wu, Y. Wu, M. Chen, G. Xing, J. Yao and J. Ren, *Toxicol. Sci.*, 2010, **118**, 435–443.
- 93 L. Zhang, Y. K. Lau, W. Xia, G. N. Hortobagyi and M. C. Hung, *Clin. Cancer Res.*, 1999, **5**, 343–353.
- 94 Y. Y. Chen, S. Y. Chiang, J. G. Lin, Y. S. Ma, C. L. Liao, S. W. Weng, T. Y. Lai and J. G. Chung, *Int. J. Oncol.*, 2010, **36**, 1113–1120.
- 95 Y. Y. Chen, S. Y. Chiang, J. G. Lin, J. S. Yang, Y. S. Ma, C. L. Liao, T. Y. Lai, N. Y. Tang and J. G. Chung, *Anticancer Res.*, 2010, **30**, 945–951.
- 96 J. J. Champoux, *Annu. Rev. Biochem.*, 2001, **70**, 369–413.
- 97 K. Hevener, T. A. Verstak, K. E. Lutat, D. L. Riggsbee and J. W. Mooney, *Acta Pharm. Sin. B*, 2018, **8**, 844–861.
- 98 G. Capranico, J. Marinello and G. Chillemi, *J. Med. Chem.*, 2017, **60**, 2169–2192.
- 99 M. N. Drwal, K. Agama, L. P. Wakelin, Y. Pommier and R. Griffith, *PLoS One*, 2011, **6**, e25150.
- 100 P. J. Smith, N. J. Blunt, R. Desnoyers, Y. Giles and L. H. Patterson, *Cancer Chemother. Pharmacol.*, 1997, **39**, 455–461.
- 101 S. R. McKeown, M. V. Hejmadi, I. A. McIntyre, J. J. McAleer and L. H. Patterson, *Br. J. Cancer*, 1995, **72**, 76–81.
- 102 J. F. Kou, C. Qian, J. Q. Wang, X. Chen, L. L. Wang, H. Chao and L. N. Ji, *J. Biol. Inorg. Chem.*, 2012, **17**, 81–96.
- 103 C. Hotzel, A. Marotto and U. Pindur, *Eur. J. Med. Chem.*, 2003, **38**, 189–197.
- 104 K. Pors, Z. Paniwnyk, P. Teesdale-Spittle, J. A. Plumb, E. Willmore, C. A. Austin and L. H. Patterson, *Mol. Cancer Ther.*, 2003, **2**, 607–610.
- 105 J. K. Son, S. J. Jung, J. H. Jung, Z. Fang, C. S. Lee, C. S. Seo, D. C. Moon, B. S. Min, M. R. Kim and M. H. Woo, *Chem. Pharm. Bull.*, 2008, **56**, 213–216.
- 106 A. Bielawska, K. Kosk and K. Bielawski, *Pol. J. Pharmacol.*, 2001, **53**, 283–287.
- 107 S. M. Wojtowicz-Praga, R. B. Dickson and M. J. Hawkins, *Invest. New Drugs*, 1997, **15**, 61–75.
- 108 B. E. Bachmeier, C. M. Iancu, M. Jochum and A. G. Nerlich, *Expert Rev. Anticancer Ther.*, 2005, **5**, 149–163.
- 109 A. R. Farina and A. R. Mackay, *Cancers*, 2014, **6**, 240–296.
- 110 C. Tabolacci, A. Lentini, P. Mattioli, B. Provenzano, S. Oliverio, F. Carlomosti and S. Beninati, *Life Sci.*, 2010, **87**, 316–324.
- 111 P. Suboj, S. Babykutty, D. R. Valiyaparambil Gopi, R. S. Nair, P. Srinivas and S. Gopala, *Eur. J. Pharm. Sci.*, 2012, **45**, 581–591.
- 112 E. H. Blackburn, *Cell*, 2001, **106**, 661–673.
- 113 J. W. Shay and S. Bacchetti, *Eur. J. Cancer*, 1997, **33**, 787–791.
- 114 H. S. Huang, I. B. Chen, K. F. Huang, W. C. Lu, F. Y. Shieh, Y. Y. Huang, F. C. Huang and J. J. Lin, *Chem. Pharm. Bull.*, 2007, **55**, 284–292.
- 115 Y. Y. Yan, L. S. Zheng, X. Zhang, L. K. Chen, S. Singh, F. Wang, J. Y. Zhang, Y. J. Liang, C. L. Dai, L. Q. Gu, M. S. Zeng, T. T. Talele, Z. S. Chen and L. W. Fu, *Mol. Pharmaceutics*, 2011, **8**, 1687–1697.
- 116 C. L. Chen, D. M. Chang, T. C. Chen, C. C. Lee, H. H. Hsieh, F. C. Huang, K. F. Huang, J. H. Guh, J. J. Lin and H. S. Huang, *Eur. J. Med. Chem.*, 2013, **60**, 29–41.
- 117 D. Cairns, E. Michalitsi, T. C. Jenkins and S. P. Mackay, *Bioorg. Med. Chem.*, 2002, **10**, 803–807.
- 118 P. J. Perry, S. M. Gowan, A. P. Reszka, P. Polucci, T. C. Jenkins, L. R. Kelland and S. Neidle, *J. Med. Chem.*, 1998, **41**, 3253–3260.
- 119 H. S. Huang, J. F. Chiou, Y. Fong, C. C. Hou, Y. C. Lu, J. Y. Wang, J. W. Shih, Y. R. Pan and J. J. Lin, *J. Med. Chem.*, 2003, **46**, 3300–3307.
- 120 M. L. Bochman, K. Paeschke and V. A. Zakian, *Nat. Rev. Genet.*, 2012, **13**, 770–780.
- 121 N. Kosiol, S. Juranek, P. Brossart, A. Heine and K. Paeschke, *Mol. Cancer*, 2021, **20**, 40.
- 122 J. Blasiak, *Curr. Med. Chem.*, 2017, **24**, 1488–1503.
- 123 A. Das and S. Dutta, *ACS Omega*, 2021, **6**, 18344–18351.
- 124 S. Wang, W. W. Yan, M. He, D. Wei, Z. J. Long and Y. M. Tao, *Pharmacol. Rep.*, 2020, **72**, 1383–1396.
- 125 Z. Zhang, X.-H. Wu, F.-Q. Sun, F. Shan, J.-C. Chen, L.-M. Chen, Y.-S. Zhou and W.-J. Mei, *Inorg. Chim. Acta*, 2014, **418**, 23–29.
- 126 N. S. Sirazhetdinova, V. A. Savelyev, D. S. Baev, T. S. Golubeva, L. S. Klimenko, T. G. Tolstikova, J. Ganbaatar and E. E. Shults, *Med. Chem. Res.*, 2021, **30**, 1541–1556.
- 127 S. Roy, A. Ali, M. Kamra, K. Muniyappa and S. Bhattacharya, *Eur. J. Med. Chem.*, 2020, **195**, 112202.



- 128 E. De Moliner, S. Moro, S. Sarno, G. Zagotto, G. Zanotti, L. A. Pinna and R. Battistutta, *J. Biol. Chem.*, 2003, **278**, 1831–1836.
- 129 G. Maurer, B. Tarkowski and M. Baccarini, *Oncogene*, 2011, **30**, 3477–3488.
- 130 J. Zhang, P. L. Yang and N. S. Gray, *Nat. Rev. Cancer*, 2009, **9**, 28–39.
- 131 L. Zhang, Y. K. Lau, L. Xi, R. L. Hong, D. S. Kim, C. F. Chen, G. N. Hortobagyi, C. Chang and M. C. Hung, *Oncogene*, 1998, **16**, 2855–2863.
- 132 A. Muto, M. Hori, Y. Sasaki, A. Saitoh, I. Yasuda, T. Maekawa, T. Uchida, K. Asakura, T. Nakazato, T. Kaneda, M. Kizaki, Y. Ikeda and T. Yoshida, *Mol. Cancer Ther.*, 2007, **6**, 987–994.
- 133 C. R. Faltynek, J. Schroeder, P. Mauvais, D. Miller, S. Wang, D. Murphy, R. Lehr, M. Kelley, A. Maycock, W. Michne, *et al.*, *Biochemistry*, 1995, **34**, 12404–12410.
- 134 Y. Shi, C. H. Wang and X. G. Gong, *Biol. Pharm. Bull.*, 2008, **31**, 1075–1078.
- 135 W. Wätjen, S. S. Ebada, A. Bergermann, Y. Chovolou, F. Totzke, M. H. G. Kubbutat, W. Lin and P. Proksch, *Arch. Toxicol.*, 2017, **91**, 1485–1495.
- 136 G. Cozza, M. Mazzorana, E. Papinutto, J. Bain, M. Elliott, G. di Maira, A. Gianoncelli, M. A. Pagano, S. Sarno, M. Ruzzene, R. Battistutta, F. Meggio, S. Moro, G. Zagotto and L. A. Pinna, *Biochem. J.*, 2009, **421**, 387–395.
- 137 S. C. Robson, J. Sévigny and H. Zimmermann, *Purinergic Signalling*, 2006, **2**, 409–430.
- 138 V. Umansky, I. Shevchenko, A. V. Bazhin and J. Utikal, *Cancer Immunol. Immunother.*, 2014, **63**, 1073–1080.
- 139 S. S. Virtanen, A. Kukkonen-Macchi, M. Vainio, K. Elima, P. L. Härkönen, S. Jalkanen and G. G. Yegutkin, *Mol. Cancer Res.*, 2014, **12**, 1863–1874.
- 140 Y. Baqi, *Drug discovery today*, 2016, **21**, 1571–1577.
- 141 M. J. Pang, Z. Yang, X. L. Zhang, Z. F. Liu, J. Fan and H. Y. Zhang, *Acta Pharmacol. Sin.*, 2016, **37**, 1623–1640.
- 142 L. Ma, Y. Yang, Z. Yin, M. Liu, L. Wang, L. Chen, L. Zhu and H. Yang, *Biomed. Pharmacother.*, 2017, **90**, 615–625.
- 143 K. A. Manu, M. K. Shanmugam, T. H. Ong, A. Subramaniam, K. S. Siveen, E. Perumal, R. P. Samy, P. Bist, L. H. Lim, A. P. Kumar, K. M. Hui and G. Sethi, *PLoS One*, 2013, **8**, e57015.
- 144 J. Ma, H. Lu, S. Wang, B. Chen, Z. Liu, X. Ke, T. Liu and J. Fu, *Int. J. Oncol.*, 2015, **46**, 1619–1628.
- 145 S. K. Koerner, J. I. Hanai, S. Bai, F. E. Jernigan, M. Oki, C. Komaba, E. Shuto, V. P. Sukhatme and L. Sun, *Eur. J. Med. Chem.*, 2017, **126**, 920–928.
- 146 G. Xie, X. Zhu, Q. Li, M. Gu, Z. He, J. Wu, J. Li, Y. Lin, M. Li, Z. She and J. Yuan, *Br. J. Pharmacol.*, 2010, **159**, 689–697.
- 147 K. Kamiya, W. Hamabe, S. Tokuyama, K. Hirano, T. Satake, Y. Kumamoto-Yonezawa, H. Yoshida and Y. Mizushima, *Food Chem.*, 2010, **118**, 725–730.
- 148 H. K. Choi, H. Ryu, A. R. Son, B. Seo, S. G. Hwang, J. Y. Song and J. Ahn, *Biomed. Pharmacother.*, 2016, **79**, 308–314.
- 149 A. P. Li, *Chem.-Biol. Interact.*, 2004, **150**, 27–33.
- 150 L. E. Sendelbach, *Toxicology*, 1989, **57**, 227–240.
- 151 Y. Liu, M. S. T. Mapa and R. L. Sprando, *Food Chem. Toxicol.*, 2020, **140**, 111313.
- 152 Y. Wang, J. Chen, L. Ge, D. Wang, X. Cai, L. Huang and C. Hao, *Dyes Pigm.*, 2009, **83**, 276–280.
- 153 R. B. Semwal, D. K. Semwal, S. Combrinck and A. Viljoen, *Phytochemistry*, 2021, **190**, 112854.
- 154 K. Oshida, M. Hirakata, A. Maeda, T. Miyoshi and Y. Miyamoto, *J. Appl. Toxicol.*, 2011, **31**, 790–800.
- 155 Q. He, K. Liu, S. Wang, H. Hou, Y. Yuan and X. Wang, *Drug Chem. Toxicol.*, 2012, **35**, 149–154.
- 156 N. Yang, M. Ruan and S. Jin, *Gastroenterol. Hepatol.*, 2020, **43**, 266–272.
- 157 Y. Li, Q. Q. Xu, C. S. Shan, Y. H. Shi, Y. Wang and G. Q. Zheng, *Front. Pharmacol.*, 2018, **9**, 943.
- 158 Q. Zhao, X. Wang, A. Chen, X. Cheng, G. Zhang, J. Sun, Y. Zhao, Y. Huang and Y. Zhu, *Int. J. Mol. Med.*, 2018, **41**, 2802–2812.
- 159 F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton and V. Préat, *J. Controlled Release*, 2012, **161**, 505–522.
- 160 Y. Bae, T. A. Diezi, A. Zhao and G. S. Kwon, *J. Controlled Release*, 2007, **122**, 324–330.
- 161 F. M. Veronese, O. Schiavon, G. Pasut, R. Mendichi, L. Andersson, A. Tsirk, J. Ford, G. Wu, S. Kneller, J. Davies and R. Duncan, *Bioconjugate Chem.*, 2005, **16**, 775–784.
- 162 E. L. Ferguson, A. Scomparin, H. Hailu and R. Satchi-Fainaro, *J. Drug Targeting*, 2017, **25**, 818–828.
- 163 B. Surnar and M. Jayakannan, *Biomacromolecules*, 2016, **17**, 4075–4085.
- 164 D. Gu, K. Ladewig, M. Klimak, D. Haylock, K. M. McLean, A. J. O'Connor and G. G. Qiao, *Polym. Chem.*, 2015, **6**, 6475–6487.
- 165 S.-X. Feng, J. Hao, T. Chen and S. X. Qiu, *Helv. Chim. Acta*, 2011, **94**, 1843–1849.
- 166 J. Koyama, I. Morita, K. Tagahara, Y. Nobukuni, T. Mukainaka, M. Kuchide, H. Tokuda and H. Nishino, *Cancer Lett.*, 2002, **182**, 135–139.
- 167 J. Koyama, I. Morita, K. Tagahara, M. Ogata, T. Mukainaka, H. Tokuda and H. Nishino, *Cancer Lett.*, 2001, **170**, 15–18.

